

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 January 2012 (26.01.2012)

(10) International Publication Number
WO 2012/010843 A1

(51) International Patent Classification:
C07D 217/26 (2006.01)

(21) International Application Number:
PCT/GB2011/001096

(22) International Filing Date:
21 July 2011 (21.07.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/366,367 21 July 2010 (21.07.2010) US

(71) Applicant (for all designated States except US):
SPINIFEX PHARMACEUTICALS PTY LTD
[AU/AU]; South Yarra Corporate Centre, Suite T18, Level 1, 122 Toorak Road, South Yarra, Victoria 3141 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MCCARTHY, Thomas, David** [AU/AU]; 40 Tooronga Road, Malvern East, Victoria 3145 (AU). **KELLY, Peter, Michael** [GB/NZ]; 36 Rimu Road, Kelburn, Wellington (NZ). **BOYLE, Craig, James, Stewart** [GB/GB]; 18 Whitton Close, Swavesey, Cambs CB24 4RT (GB). **EBERLIN, Alexander, Redvers** [GB/GB]; 6 Scholars Walk, Cambridge CB4 1EJ (GB).

(74) Agents: **NAISMITH, Robert, Stewart** et al.; Marks & Clerk LLP, Aurora, 120 Bothwell Street, Glasgow G2 7JS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE

(57) Abstract: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.



WO 2012/010843 A1

- 1 -

SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE**Related Applications**

- 5 **[0001]** This application claims the benefit of U.S. Provisional Application Serial No. 61/366,367, filed July 21, 2010, which is hereby incorporated by reference in its entirety.


Field of the Invention

- 10 **[0002]** (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.

Background of the Invention

- 15 **[0003]** (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid, which is one enantiomer of the racemate known as PD 126055, is an angiotensin II type 2 (AT₂) receptor antagonist and is described in US 5,246,943 and in Klutchko *et al.*, 1994, Bioorg. & Med. Chem. Lett., 4:57-62.

- 20 **[0004]** AT₂ receptor antagonists have recently been identified as useful in treating pain, particularly inflammatory pain (WO 2007/106938) and neuropathic pain (WO 2006/066361) and (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid:



Compound 1

25

has been identified as a drug candidate.

- 2 -

[0005] Compound 1 has been obtained from the racemate by recrystallization of the α -methylbenzylamine salt (US 5,246,943). However, this method does not provide adequate quantities of Compound 1 with required high levels of chemical and enantiomeric purity necessary for pharmaceutical purposes.

5

[0006] Although the racemate, ie: (*R,S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-phenylmethoxy)-3-isoquinoline carboxylic acid, is a crystalline compound and two different crystalline forms have been identified by the inventors, Compound 1 is an amorphous compound and despite significant effort, no crystalline form of the compound has been identified. There are significant difficulties in developing Compound 1 for pharmaceutical purposes including:

10

15

20

1. the amorphous form is difficult to purify to levels required for pharmaceutical purposes without resorting to expensive and time consuming chromatography methods;
2. the amorphous form of Compound 1 retains residual solvents which are difficult to remove to acceptable levels for pharmaceutical use; and
3. the amorphous form of Compound 1 has very low aqueous solubility and this limits its oral bioavailability.

[0007] There is a need for a form of Compound 1 that is suitable for pharmaceutical development, including a form that can be obtained in large quantities with acceptable chemical purity and enantiomeric purity and that has acceptable aqueous solubility.

25

[0008] The present invention is predicated, at least in part, by the discovery that the sodium salt of Compound 1 had a propensity to form highly crystalline solvates that not only allow this material to be manufactured with improved chemical purity but also allows the enantiomeric purity to be improved by recrystallization in the event that some epimerization occurs at the chiral 3-position of the tetrahydroisoquinoline ring during the manufacturing process. The sodium salt was also found to have good oral bioavailability characteristics.

30

Summary of the Invention

[0009] In a first aspect there is provided the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and solvates thereof.

[0010] In a particular embodiment, the sodium salt is in an amorphous form. In other embodiments, the sodium salt is in the form of a crystalline solvate, especially an ethanolate, *iso*-propanolate or hydrate. In some embodiments, the hydrate is a monohydrate, dihydrate, trihydrate, tetrahydrate, or a full or fractional hydrate in between one and five. In some embodiments, the hydrate has about 2 to about 5 molecules of water.

[0011] In another aspect there is provided (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.

[0012] In a particular embodiment, the compound has an enantiomeric purity of >97% ee and/or >96% chemical purity.

[0013] In another aspect of the invention there is provided a pharmaceutical composition comprising the (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid, its sodium salt or a solvate of the sodium salt together with a pharmaceutically acceptable carrier, diluent or excipient.

[0014] In some embodiments, the composition comprises the sodium salt. In some embodiments, the composition is in a solid form, especially for oral delivery. In some embodiments, the sodium salt is in an amorphous form.

[0015] In yet another aspect of the invention, there is provided a method of preparing the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid comprising:

- 4 -

- (i) treating (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid with sodium alkoxide;
- (ii) forming a crystalline alcohol solvate of the resulting sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid; and
- (iii) recrystallizing the solvate formed in step (ii).

[0016] In one embodiment, the sodium alkoxide is sodium ethoxide. In a particular embodiment the crystalline solvate is the ethanol or *iso*-propanol solvate, especially the *iso*-propanol solvate.

[0017] In some embodiments, the solvate molecule of the crystalline alcohol solvate formed in step (ii) is exchanged for another solvate molecule before, during or after step (iii). In a particular embodiment, the crystalline alcohol solvate obtained in step (ii) is an ethanol solvate and recrystallization in step (iii) is achieved in a solvent comprising *iso*-propanol such that the crystalline solvate obtained in step (iii) is the *iso*-propanol solvate of the sodium salt of Compound 1. In some embodiments, the recrystallization of step (iii) is performed in a non-aqueous organic solvent.

[0018] The method may further comprise the step of exchanging the alcohol within the solvate for water molecules to prepare amorphous or crystalline hydrates of the sodium salt.


[0019] The method may further comprise the step of drying the alcohol solvate or hydrate to provide the amorphous sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid. In some embodiments, drying is by lyophilization.

[0020] The method may further comprise the step of acidifying the sodium salt to provide (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.

- 5 -

[0021] In yet a further aspect, there is provided a method of preparing an alcohol solvate of the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid comprising the steps of:

- 5 (i) acylating the isoquinoline nitrogen atom of (*S*)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid with an activated cyclic amide of the formula:



wherein ring A is a 5 membered nitrogen-containing heterocycle; and

- 10 (ii) treating the product of step (i) with an alkoxide salt in an alcohol solvent.

[0022] In some embodiments, the 5 membered nitrogen-containing heterocycle is pyrazole, pyrrole, imidazole, 1,2,3-triazole or 1,2,4-triazole, especially pyrazole. In some embodiments the alkoxide salt is sodium ethoxide. In some embodiments the alcohol solvent is ethanol.

[0023] All publications and patent applications mentioned in this specification are incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Brief Description of the Drawings

[0024] Figure 1 illustrates the characteristic X-ray powder diffraction pattern of a crystalline sodium salt of Compound 2.

25

[0025] Figure 2 illustrates the characteristic X-ray powder diffraction pattern of a crystalline ethanol solvate of the sodium salt (Compound 4).

- 6 -

[0026] Figure 3 illustrates the characteristic X-ray powder diffraction pattern of a crystalline *iso*-propanol solvate of the sodium salt (Compound 5).

5 [0027] Figure 4 illustrates the characteristic X-ray powder diffraction pattern of a crystalline hydrate of the sodium salt that has at least three water molecules (Compound 6).

10 [0028] Figure 5 illustrates the characteristic X-ray powder diffraction pattern of a crystalline hydrate of the sodium salt that has about two water molecules (Compound 7).

[0029] Figure 6 illustrates a characteristic solid state ^{13}C NMR spectrum of an amorphous sodium salt of Compound 2.

15 [0030] Figure 7 illustrates a characteristic solid state ^{13}C NMR spectrum of a crystalline ethanol solvate of the sodium salt (Compound 4).

[0031] Figure 8 illustrates a characteristic solid state ^{13}C NMR spectrum of a crystalline *iso*-propanol solvate of the sodium salt (Compound 5).

20 [0032] Figure 9 illustrates a characteristic solid state ^{13}C NMR spectrum of a crystalline hydrate of the sodium salt that has at least three water molecules (Compound 6).

25 [0033] Figure 10 illustrates a characteristic solid state ^{13}C NMR spectrum of a crystalline hydrate of the sodium salt that has about two water molecules (Compound 7).

[0034] Figure 11 depicts the mean plasma concentration of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid (compound 1) over time following oral administration of Compounds 1, 2 (amorphous sodium salt), 6, and 7 to dogs. Figure 11A depicts the mean plasma concentration time curves on a linear scale and Figure 11B depicts the mean plasma concentration time curves on a log scale.


30

- 7 -

[0035] Figure 12A provides the C_{max} of the free acid Compound 1 following oral administration of Compounds 1, 2 (amorphous sodium salt), 6, and 7 to dogs. Figure 12B provides the AUC (0-inf) of the free acid Compound 1 following oral administration of Compounds 1, 2 (amorphous sodium salt), 6, and 7 to dogs.

Detailed Description of the Invention

[0036] The sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid (hereinafter referred to as Compound 2) has the formula:




Compound 2

[0037] This compound is an AT₂ receptor antagonist with pharmaceutical uses in treating pain, especially inflammatory and neuropathic pain. Compound 1 and its racemic mixture have been previously identified as an AT₂ receptor antagonist. However, the sodium salt (Compound 2) has now been found to have particular advantages in relation to ease of manufacture, purity and oral bioavailability not found in the free acid (Compound 1) or other salts.

[0038] While the racemic form is crystalline, the single enantiomer represented by Compound 1 has not been isolated in a crystalline form and therefore purification to pharmaceutically acceptable levels is difficult, including removal of its (*R*)-enantiomer (Compound 3):

- 8 -



Compound 3

[0039] Furthermore, epimerization at the chiral 3-position of Compound 1 can occur under some manufacturing conditions and therefore obtaining and maintaining
5 Compound 1 with a high enantiomeric purity can be a challenge.


[0040] The present inventors have found that the sodium salt, Compound 2, can be isolated in crystalline form as a solvate, particularly an alcohol solvate. This may be achieved directly from the preparation of Compound 1 and therefore purification by
10 crystallization is possible and high enantiomeric purity may be achieved. Furthermore, if epimerization of the chiral centre at the 3-position occurs, crystallization can be used to remove the unwanted enantiomer and to improve enantiomeric purity. The solvates may also be exchanged with one another and conversion to hydrate forms with pharmaceutically acceptable purity and residual solvent levels can be achieved. These
15 hydrate forms include crystalline forms as well as an amorphous form, with the latter being prepared by lyophilization.

[0041] In a particular embodiment, Compound 2 is in amorphous form. In one such embodiment, the amorphous form exhibits a solid state ^{13}C NMR spectrum comprising
20 peaks at about 55.2, 109.8, 128.4 and 151.7 ppm. In another such embodiment, the amorphous form exhibits a solid state ^{13}C NMR spectrum substantially the same as Figure 6. In another embodiment, the solid state ^{13}C NMR spectrum has peaks at about 26.2, 29.8, 39.0, 41.9, 45.7, 55.2, 60.4, 73.6, 94.4, 109.8, 121.3, 128.4, 139.9, 145.0, 151.7, 172.2, 175.7 and 178.8 ppm.

- 9 -

- [0042] In another embodiment, Compound 2 is in a crystalline form. In one such embodiment, the non-solvated sodium salt crystalline form exhibits an XRPD pattern comprising at least one peak at about 9.6 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising a peak at about 9.6 degrees 2θ and comprising at least one peak selected from the group consisting of about 6.0 and 19.6 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising a peak at about 9.6 degrees 2θ , at least one peak selected from the grouping consisting of about 6.0, and 19.6 degrees 2θ , and at least one peak selected from the group consisting of about 14.0, 17.9, 20.6, 21.8, 23.3 and 23.9 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern substantially the same as Figure 1. In another such embodiment, the non-solvated crystalline form has an X-ray diffraction pattern with peaks at $2\theta = 5.5, 6.0, 6.9, 8.5, 9.6, 11.0, 13.3, 14.0, 16.1, 16.7, 17.9, 18.4, 19.6, 20.6, 21.8, 22.3, 23.3, 23.9, 25.5, 26.3$ and 27.6 .
- [0043] In some embodiments, the solvate is formed from water or an alcoholic solvent, especially water, ethanol or *iso*-propanol.

- [0044] In one embodiment, the solvate of the sodium salt is the ethanol solvate (ethanolate) (Compound 4):




- [0045] In one embodiment, this compound can be isolated in a crystalline form. In one such embodiment the ethanol solvate exhibits an X-ray powder diffraction ("XRPD") pattern comprising a peak at about 14.3 degrees 2θ . In another such embodiment, the ethanol solvate sodium salt crystalline form exhibits XRPD pattern comprising a peak at

- 10 -

about 14.7 degrees 2θ . In another such embodiment, the ethanol solvate sodium salt crystalline form exhibits XRPD pattern comprising a peak at least two of the group comprising about 14.3, 14.7, 26.9, and 29.7 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern substantially the same as Figure 2. In another such embodiment, the crystalline form has an X-ray diffraction pattern with peaks at $2\theta =$ 5.5, 6.7, 8.0, 8.7, 9.3, 11.1, 13.4, 14.3, 14.7, 15.8, 16.1, 16.6, 17.4, 17.8, 18.8, 20.3, 20.9, 21.4, 22.2, 22.8, 24.2, 25.4, 26.9, 27.6, 28.7, 29.7, 30.3, 31.3, 32.1, 33.5, 35.7 and 41.0.

[0046] In one embodiment, the ethanol solvate of the sodium salt crystalline form exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 18.4, about 139.7, and about 141.4 ppm. In another such embodiment the ethanol solvate of the sodium salt crystalline form exhibits a solid state ^{13}C NMR spectrum substantially the same as Figure 7. In another embodiment, the solid state ^{13}C NMR spectrum has peaks at about 18.4, 25.9, 28.6, 38.1, 41.9, 47.0, 52.0, 54.1, 55.6, 57.5, 74.1, 81.1, 110.8, 118.5, 126.4, 128.1, 137.6, 139.7, 141.4, 143.9, 151.3, 171.6 and 180.2 ppm.

[0047] In another embodiment, the solvate of the sodium salt is the *iso*-propanol solvate (*iso*-propanolate) (Compound 5):



[0048] This compound can be isolated in a crystalline form. In one such embodiment, the *iso*-propanol solvate of the sodium salt crystalline form exhibits an XRPD pattern comprising at least one peak selected from the group consisting of about 26.0, 26.6, 27.2, 28.3, and 29.3 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising at least two peaks selected from the group consisting of about

- 11 -

25.0, 26.0, 26.6, 27.2, 28.3, and 29.3 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising at least one peak selected from the grouping consisting of about 26.0, 26.6, 27.2, 28.3, and 29.3 degrees 2θ , and at least one peak selected from the group consisting of about 10.8, 14.0, 21.1, 21.9, and 22.5 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern substantially the same as Figure 3. In another embodiment, this *iso*-propanol solvate crystalline form has an X-ray diffraction pattern with peaks at $2\theta = 5.4, 6.6, 7.9, 8.6, 9.2, 10.8, 13.4, 14.0, 15.9, 16.4, 17.3, 17.6, 18.6, 20.0, 20.5, 21.1, 21.9, 22.5, 23.0, 24.0, 25.0, 25.5, 26.0, 26.6, 27.2, 28.3$ and 29.3.


10

[0049] In one embodiment, the *iso*-propanol solvate of the sodium salt crystalline form exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 63.1, and about 140.7 ppm. In another such embodiment the *iso*-propanol solvate of the sodium salt crystalline form exhibits a solid state ^{13}C NMR spectrum substantially the same as Figure 8. In another embodiment, the solid state ^{13}C NMR spectrum has peaks at about 25.1, 28.0, 41.4, 46.8, 48.2, 53.8, 55.8, 56.8, 58.1, 63.1, 74.0, 111.0, 118.7, 126.5, 128.0, 137.7, 140.7, 143.7, 151.4, 171.2, 173.2 and 180.0 ppm.

15

[0050] In another embodiment, the solvate of the sodium salt is the trihydrate solvate (Compound 6) containing three molecules of water for every molecule of Compound 2.

20



[0051] Some studies indicate that Compound 6 may have four or more molecules (a fractional hydrate) of water for every molecule of Compound 2. Regardless of the exact amount of water, the hydrate of Compound 6 can be isolated in crystalline form. In one

25

- 12 -


such embodiment, the hydrate of the sodium salt crystalline form having between three and 5 water molecules exhibits an XRPD pattern comprising a peak at about 15.2 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising a peak at about 15.2 degrees, and at least two peaks selected from the group consisting of about 4.8, 7.3, 12.0, 12.6, 23.5, and 24.5 degrees 2θ . In another such embodiment, the crystalline form exhibits an XRPD pattern substantially the same as Figure 4. In another embodiment, this hydrate crystalline form has an X-ray diffraction pattern with peaks at $2\theta = 4.8, 5.5, 7.3, 8.3, 9.9, 12.0, 12.6, 15.2, 16.7, 17.2, 17.9, 19.0, 21.5, 23.5$ and 24.5 .

10

[0052] In one embodiment, the hydrate of the sodium salt crystalline form having about 3 to less than 5 water molecules exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 53.7, about 122.9, and about 128.1 ppm. In another such embodiment the hydrate of the sodium salt crystalline form having about 3 to less than 5 water molecules exhibits a solid state ^{13}C NMR spectrum substantially the same as Figure 9. In another embodiment, the solid state ^{13}C NMR spectrum has peaks at about 23.7, 26.2, 28.4, 38.1, 45.5, 47.6, 53.7, 55.8, 59.3, 74.0, 108.6, 110.5, 120.5, 122.9, 128.1, 130.4, 137.7, 139.8, 143.9, 145.3, 150.9, 152.0, 171.6, 173.3 and 177.3 ppm

15

20 [0053] In yet another embodiment, the solvate of the sodium salt is the dihydrate solvate (Compound 7) containing two molecules of water for every molecule of Compound 2.



25 [0054] Some studies indicate that Compound 7 may have slightly less than two, but more than one molecule of water (a fractional hydrate) for every molecule of Compound 2.

- 13 -

Regardless of the exact amount of water, the hydrate of Compound 7 can be isolated in crystalline form. In one such embodiment, the hydrate of the sodium salt crystalline form having 1-2 water molecules exhibits an XRPD pattern comprising at least one peak at about 19.3 degrees 2 θ . In another such embodiment, the crystalline form exhibits an XRPD pattern comprising peaks at about 19.3 and 18.2 degrees 2 θ . In another such embodiment, the crystalline form exhibits an XRPD pattern substantially the same as Figure 5. In another embodiment, this hydrate crystalline form has an X-ray diffraction pattern with peaks at 2 θ = 4.8, 5.5, 7.3, 8.2, 12.1, 12.8, 15.8, 16.9, 18.2, 19.3 and 25.6.

[0055] In one embodiment, the hydrate of the sodium salt crystalline form having about 1-2 water molecules exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 55.7, about 128.2, and about 151.3 ppm. In another such embodiment the hydrate of the sodium salt crystalline form having about 1-2 water molecules exhibits a solid state ^{13}C NMR spectrum substantially the same as Figure 10. In another embodiment, the solid state ^{13}C NMR has peaks at about 25.8, 28.2, 46.6, 55.7, 73.7, 75.1, 109.3, 119.7, 128.2, 137.8, 139.6, 144.7, 151.3, 172.1 and 178.2 ppm.

[0056] As used herein, the term "enantiomeric purity" refers to the percentage of (*S*)-enantiomer present compared to the unwanted (*R*)-enantiomer. For example a purity of 90% has 90% (*S*)-enantiomer and 10% (*R*)-enantiomer and a purity of 100% has only (*S*)-enantiomer and no (*R*)-enantiomer. In particular embodiments, the purity of the (*S*)-enantiomer is high, that is above 80%, especially above 85%, 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99% and includes 100%. Enantiomeric purity may also be reported as enantiomeric excess (ee). Enantiomeric excess is usually expressed as a percentage calculated by the following equation:

$$((R-S)/(R+S)) \times 100 = \%ee$$

where R and S are the respective fractions of the enantiomers such that $R + S = 1$. In particular embodiments, the ee of the (*S*)-enantiomer is high, that is above 80%, especially above 85%, 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99% and includes 100%.

- 14 -

[0057] As used herein, the term "chemical purity" refers to the percentage of impurities present in the product. Impurities may be in the form of, for example, the presence of unwanted solvents, degradation products or oxidation products. In particular embodiments the chemical purity is high, that is above 80% of the product is (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline
5 carboxylic acid, especially above 85%, 87.5%, 90%, 92.5%, 95%, 96%, 97%, 98%, 99% and includes 100%.

[0058] The term "substantially pure form" refers to a product having greater than 96%
10 chemical purity, especially greater than 97%, 98% or 99% and more especially 100% chemical purity and/or greater than 97% ee, especially greater than 98% or 99% ee and more especially 100% ee.

[0059] As used herein, the meaning of the term "about" depends upon the context in
15 which it is used. When used with respect to the position of a peak on an x-ray powder diffraction (XRPD) pattern, the term "about" includes peaks within ± 0.1 degrees 2θ of the stated position. For example, as used herein, an XRPD peak at "about 10.0 degrees 2θ " means that the stated peak occurs from 9.9 to 10.1 degrees 2θ . When used with respect to the position of a peak on a solid state ^{13}C NMR spectrum, the term "about"
20 includes peaks within ± 0.2 ppm of the stated position. For example, as used herein, a ^{13}C NMR spectrum peak at "about 100.0 ppm" means that the stated peak occurs from 99.8 to 100.2 ppm.

[0060] Synthetic methods for the preparation of Compound 1 are known in the art. The
25 synthesis of the racemic mixture containing Compound 1 and its (R)-enantiomer Compound 3, followed by resolution of the enantiomers using chiral salt formation is described in US 5,246,943 and Klutchko *et al.*, Bioorg. & Med. Chem. Lett., 1994, 4:57-62. The chiral salt used for resolution was 1-(-)- α -methylbenzylamine.

[0061] The sodium salt, Compound 2, can be obtained by treating Compound 1 with an
30 aqueous solution of sodium hydroxide. However, this method prepares Compound 2 as

- 15 -

an oily residue or gum rather than a crystalline solid. Crystalline forms of the sodium salt are not obtained unless solvent systems are chosen that lead to the formation of crystalline solids in the form of different solvates. For example, the ethanol solvate, Compound 4, can be obtained by taking the non-crystalline form of Compound 2 prepared using an aqueous solution of sodium hydroxide and treating it with ethanol or more preferably by treating Compound 1 with sodium ethoxide in ethanol. Similarly, the *iso*-propanol solvate, Compound 5, can be prepared by taking the non-crystalline form of Compound 2 prepared using an aqueous solution of sodium hydroxide and treating it with *iso*-propanol. Compound 5 could also be prepared by treating Compound 1 with sodium *iso*-propoxide in *iso*-propanol containing solvent systems.

[0062] Compound 2 or its solvates may also be obtained by recrystallizing an alcohol solvate of Compound 2 in an organic solvent or an aqueous organic solvent (organic solvent with added percentage of water). Crystalline solvates were obtained by recrystallization in ethyl acetate (EtOAc)/10% water, methylethylketone (MEK), 1-propanol, EtOAc, tert-butylmethyl ether (TBME) and hydrocarbon solvents such as heptane. Recrystallization from acetonitrile gave a non-solvated crystalline form of the sodium salt.

[0063] The hydrates, Compounds 6 and 7, can be obtained by exposure of the crystalline ethanolate or *iso*-propanolate to moisture, especially atmospheric moisture. At high humidity such as 70% relative humidity, the Compound 6 hydrate is formed, in moderate humidity such as 40% relative humidity, the Compound 7 hydrate is formed. Upon drying or lyophilization of the different hydrate forms, the amorphous sodium salt (Compound 2) is produced.


[0064] The amorphous form of Compound 2 can also be formed by lyophilization of an alcohol solvate of Compound 2 in water.

[0065] Alternatively, Compound 2 can be prepared by asymmetric synthesis and the sodium salt isolated as a crystalline solvate at the end of the synthesis. There are

- 16 -

methods known in the art for preparing non-natural chiral α -amino acids (for example, Burk *et al.*, *J. Am. Chem. Soc.*, 1993, 115, 10125-10138) and such methods can be applied to the synthesis of a chiral *ortho*-phenylmethoxy-*meta*-methoxy-phenylalanine. Care must be taken to use conditions that are sufficiently mild as to allow the retention of the pendent O-benzyl group.

[0066] Once prepared, the chiral phenylalanine derivative can be transformed into a 1,2,3,4-tetrahydroisoquinoline using the Pictet-Spengler reaction as shown in Scheme 1 and described in US 5,246,943.




Scheme 1

[0067] Acylation of the isoquinoline nitrogen atom may be achieved by reaction of the isoquinoline with 2,2-diphenylethanoic acid which has been activated for reaction to form an amide bond, for example, 2,2-diphenylethanoic acid chloride, anhydride or a cyclic active amide. This reaction must be carefully controlled as yields can be decreased by the formation of dimeric, esterified or epimerized byproducts. Side reactions can be avoided or reduced by using anhydrous conditions and protecting the carboxylic acid during acylation of the isoquinoline nitrogen with an acid chloride. For example, during the formation of the amide bond using 2,2-diphenylethanoic acid chloride, an easily hydrolyzed protecting group, such as a trimethylsilyl group, that is hydrolyzed during aqueous work up, may be used to prevent or reduce side reactions at the carboxylic acid. Suitable protecting groups are known in the art and may be found in Greene and Wuts, *Protective Groups in Organic Synthesis*, 3rd Edition, 1999, John Wiley & Sons.

- 17 -

[0068] Use of a cyclic active amide of 2,2-diphenylethanoic acid reduces the need for this temporary protection of the isoquinoline carboxylic acid as the cyclic active amide is more selective for reaction with the isoquinoline nitrogen. The cyclic active amide may be formed by reaction of the 2,2-diphenyl ethanoic acid chloride with a 5 membered nitrogen containing heterocycle. Examples of suitable heterocycles include pyrazole, pyrrole, imidazole, 1,2,3-triazole and 1,2,4-triazole. An example using pyrazole is shown in Scheme 2.

[0069] The knowledge of different solvates and physical forms of Compound 2 is incorporated into the overall synthetic process by preparing the ethanol solvate of the sodium salt, Compound 4, for example, by adding sodium ethoxide in ethanol to the organic extract following aqueous work up of the acylation reaction and isolating the crystalline intermediate directly from the reaction mixture as shown in Scheme 2.




Scheme 2

[0070] Accordingly, in a further aspect of the invention there is provided a method of preparing an alcohol solvate of the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid comprising the steps of:

- 18 -

- (i) acylating the isoquinoline nitrogen atom of (*S*)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid with an activated cyclic amide of the formula:



- 5 wherein ring A is a 5 membered nitrogen-containing heterocycle; and
(ii) treating the product of step (i) with an alkoxide salt in an alcohol solvent.

[0071] In some embodiments, the 5 membered nitrogen-containing heterocycle is pyrazole, pyrrole, imidazole, 1,2,3-triazole or 1,2,4-triazole. In one embodiment, the 5 membered nitrogen containing heterocycle is pyrazole. In some embodiments the alkoxide salt is sodium ethoxide. In some embodiments the alcohol solvent is ethanol. In some embodiments the combination of sodium ethoxide and ethanol is used.

15 [0072] In some embodiments the product of step (i) is treated with base, such an amine base, before step (ii).

[0073] Compound 4 can be further purified by recrystallization in ethanol containing solvent systems to provide crystalline Compound 4. Likewise, if Compound 5 was prepared, it may be purified by recrystallization in an *iso*-propanol solvent system. The alcohol solvates can be converted by crystallization in a different alcohol containing solvent system. For example, Compound 5 may be made by recrystallization from *iso*-propanol or mixtures of *iso*-propanol and another polar solvent such as ethyl acetate, to give the *iso*-propanol solvate (Compound 5).

25 [0074] Compounds 4 or 5 may be stored, converted to the different crystalline forms of the hydrates of Compound 2 or dissolved in water and lyophilized to provide amorphous Compound 2.

- 19 -

[0075] The sodium salt, Compound 2, can be prepared in crystalline or amorphous forms suitable for use in a pharmaceutical composition, by treating the free acid (Compound 1), either during synthesis or after its isolation, with a sodium alkoxide, then forming a crystalline solvate.

5

[0076] As used herein, an "alkoxide" refers to an ion formed by removal of hydrogen atom from the hydroxyl group of an alcohol. Suitable alkoxides that may be used in the present invention include methoxide, ethoxide, propoxide, *iso*-propoxide and butoxide.

10 [0077] The crystalline solvate of Compound 2 may be formed by treatment with the sodium alkoxide by using a suitable solvent. For example, the ethanol solvate of Compound 2 may be formed by treatment with sodium ethoxide in ethanol. The *iso*-propanol solvate may be formed by treatment with sodium *iso*-propoxide in *iso*-propanol.

15 [0078] Once the crystalline solvate is isolated, it is recrystallized from a suitable solvent. Recrystallization of the isolated solvate may be performed or the solvate may be exchanged for another solvate before or during recrystallization. For example, the ethanol solvate may be isolated and then the ethanol molecule exchanged with an *iso*-propanol molecule to give the *iso*-propanol solvate which is recrystallized.

20

[0079] The recrystallized alcohol solvate may then be converted to hydrate forms through exposure to atmospheric moisture and/or dried or lyophilized to give amorphous Compound 2 in high chemical and enantiomeric purity. In some embodiments the crystalline alcohol solvate or hydrate is dissolved in water and lyophilized to give
25 amorphous Compound 2 in high chemical and enantiomeric purity or substantially pure form.

30

[0080] The sodium salt (Compound 2) may also be acidified to give the free acid (Compound 1) in substantially pure form.

- 20 -

[0081] Although it is possible to use the compounds of the invention in neat form, it is more suitably used in a pharmaceutical composition together with at least one pharmaceutically acceptable carrier, diluent or excipient.

5 [0082] The carrier(s), diluent(s) or excipient(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

10 [0083] Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The compounds of the invention, especially Compound 2, together with a conventional adjuvant, carrier, excipient, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form
15 may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in
20 conventional proportions, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing ten (10) milligrams or (25) milligrams of active ingredient or, more broadly, 0.1 to two hundred (200) milligrams, per tablet or capsule, are accordingly suitable representative unit dosage forms. The compounds of the present
25 invention, especially Compound 2, can be administered in a wide variety of oral and parenteral dosage forms. In a particular embodiment, amorphous Compound 2 is formulated as a solid dosage form.

30 [0084] For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. For liquid formulations, the sodium salt and its solvates are used to obtain Compound 2 at a level of

- 21 -

purity that is suitable for use in pharmaceutical compositions. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet
5 disintegrating agents, or an encapsulating material.

[0085] In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

10 [0086] In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.

[0087] In a particular embodiment the powders and tablets contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium
15 carbonate, magnesium stearate, steric acid, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, colloidal silicon dioxide, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component,
20 with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.

[0088] For preparing suppositories, a low melting wax, such as admixture of fatty acid
25 glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

[0089] Formulations suitable for vaginal administration may be presented as pessaries,
30 tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

- 22 -

5 [0090] Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.

10 [0091] The active agent may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain
15
formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle,
15 e.g., sterile, pyrogen-free water, before use.

[0092] Aqueous solutions suitable for oral use can be prepared by dissolving the active compound in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.

20

[0093] Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents. In some embodiments, where aqueous solubility and/or oral
25 bioavailability is low, for example, with Compound 1, the compound may be formulated in a lipid containing formulation such as corn oil or formulated as a gel and delivered in a capsule.

30 [0094] Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in

- 23 -

addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

5 [0095] For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening
10 agents, or colouring agents.

[0096] Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or
15 sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0097] Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided
20 in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump. To improve nasal delivery and retention the compound according to the invention may be encapsulated with cyclodextrins, or
25 formulated with their agents expected to enhance delivery and retention in the nasal mucosa.

[0098] Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with
30 a suitable propellant such as a chlorofluorocarbon (CFC) for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon

- 24 -

dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.

5 [0099] Alternatively the active ingredient may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).

10 [00100] Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.

15 [00101] In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 1 to 10 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.

20 [00102] When desired, formulations adapted to give sustained release of the active ingredient may be employed.

25 [00103] In a particular embodiment the pharmaceutical preparations are in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

30 [00104] In particular embodiments, the pharmaceutical preparations are solid oral dosage forms such as tablets or capsules.

- 25 -

[00105] The invention will now be described with reference to the following Examples which illustrate some particular aspects of the present invention. However, it is to be understood that the particularity of the following description of the invention is
5 not to supersede the generality of the preceding description of the invention.

EXAMPLES

Example 1: Classical Resolution of Racemate

[00106] A racemic mixture of Compound 1 and Compound 3 was obtained by the method of US 5246943 and subjected to resolution using chiral salt formation. Twenty chiral bases were used to separate the enantiomers as chiral salts from racemic material, containing Compound 1 and Compound 3. The resolution procedure was to provide a salt of the enantiomer Compound 1 in a crystallized solid form, from which the free acid, Compound 1, could be prepared.

10

[00107] All the chiral bases were made up to 0.5 molar concentrations in ethanol. Those that would not dissolve in ethanol were added as solids, using the masses given, so that 1.05 molar equivalents of the bases were added to each sample of the free acid. The solutions were heated to 50°C with stirring and cooled to 5°C over twenty-one hours. The results are shown in Table 1. Samples 7 and 9 recrystallized on cooling. Those that did not recrystallize were sonicated for ten minutes, and then stored in a shaker at 25°C overnight. Samples 4, 6, 12 and 19 were added as solids and did not dissolve fully at 50°C, so were matured at 25°C.

20 Table 1. Initial chiral salt resolution

Sample	Chiral base	Volume used of 0.5M solution	Mass used	Solid
1	L-Arginine	Did not dissolve	18.29mg	-
2	(R)-(+)-N-Benzyl- α -methylbenzylamine	210 μ L		-
3	(R)-(-)-2-amino-1-butanol	210 μ L		-
4	(R)-(-)-Epinephrine	Did not dissolve	19.24mg	✓
5	(S)-(+)-2-Amino-3-methyl-1-butanol (valinol)	210 μ L		-
6	(1S 2S)-2-Amino-1-(4-nitrophenyl)-1-3-propanediol	Did not dissolve	22.51mg	✓
7	(R)-(-)-amino-2-propanol	210 μ L		✓
8	(-)-Cinchonidine	210 μ L		-
9	(R)-(-)-1-Cyclohexylamine	210 μ L		✓
10	Dehydroabietylamine	210 μ L		-
11	(S)-(+)-Leucinol	210 μ L		-

- 27 -

12	L-Lysine	Did not dissolve	15.66mg	✓
13	(R)-(+)- α -Methylbenzylamine	210 μ L		-
14	(1R 2S)-(-)-N-Methylephedrine	210 μ L		-
15	N-Methyl-D-glucamine	Did not dissolve	20.70mg	-
16	(R)-(-)-2-Phenyglycinol	210 μ L		-
17	(S)-2-Pyrrolidinemethanol	210 μ L		-
18	Quinine	210 μ L		-
19	(1R 2S)-(+)-Thiomicamine	Did not dissolve	22.62mg	✓
20	N-Ethyl-D-glucamine	Did not dissolve	22.41mg	-

[00108] The six samples that gave solids were analyzed by chiral HPLC to assess any chiral resolution of the compound on salt formation and the results are shown in Table 2.

5

Table 2. Chiral HPLC analysis of salts.

Sample	4	6	7	9	12	19
Solid	Impurities present	Impurities present	-0.5	+3.0	0.0	-8.0
Liquor	0.0	Impurities present	Impurities present	+1.0	+2.0	+40.0

[00109] The material collected from Sample 19 from treatment with thiomicamine showed the greatest separation of the enantiomers. The solid isolated favoured Compound 1 over Compound 3, giving an enantiomeric excess of 8.0%. The liquor therefore favoured the enantiomer Compound 3, giving an enantiomeric excess of 40%. The analysis of the % of each enantiomer in the solid and liquor was analyzed and is shown in Table 3.

15 Table 3 – Chiral HPLC results for the thiomicamine salt.

	% Compound 3	Compound 1
Sample 19 Solid	46	54
Sample 19 Liquor	70	30

- 28 -

[00110] The solids collected were also analyzed by XRPD. Each of the solids collected gave new diffractograms that did not match either form of the free acid or the chiral base used to form the salt.

- 5 [00111] The thiomicamine salt was slurried at 25°C overnight using 70mg in 3mL of ethanol, which was then filtered and the solid was analyzed by chiral HPLC, giving an increase in the enantiomeric excess, again in favour of Compound 1. This was repeated using 10mg of the recovered solid in 600µL of ethanol, giving an increase in enantiomeric excess of 77.8% of Compound 1. A ¹H NMR after the first slurrying
10 experiment shows the thiomicamine stays intact after this process, giving a 1:1 thiomicamine salt. The results are shown in Table 4.

Table 4 – Chiral HPLC results of slurrying the thiomicamine salt.

	% Compound 3	% Compound 1	Enantiomeric excess
After first slurrying attempt	31.9	68.1	-36.2
After second slurrying attempt	11.1	88.9	-77.8

15 **Example 2: Further Chiral Resolution of Racemate**

- [00112] The racemic compound was dissolved in the appropriate solvent as set out in Table 5, using 50mg of free acid in 500µL of solvent. The chiral bases that did not dissolve fully in solution were added as solids to the free acid solution, so that all the solution contained 1.05 molar equivalents of the chiral base. The solutions were heated
20 to 50°C with stirring, and then cooled to 10°C over twenty hours.

- [00113] The solutions that did not produce a solid on cooling were placed in a sonicator for five minutes and left to stand at room temperature overnight. After this, only the solutions with L-arginine did not form a solid, from *iso*-propanol (IPA) or ethyl
25 acetate (EtOAc).

Table 5 – Second chiral salt resolution.

Sample	Chiral base	Solvent	Volume used of 0.5M solution	Mass used	Solid formation
1	L-Arginine	IPA	210µL		no solid produced
2	(R)-(-)-2-amino-1-butanol	IPA	210mL		solid formed on cooling
3	(R)-(-)-1-amino-2-propanol	IPA	210µL		solid formed on cooling
4	(R)-(-)-1-Cyclohexylethylamine	IPA	210µL		solid formed on cooling
5	L-Lysine	IPA	Did not dissolve	15.66mg	solid formed on cooling
6	(R)-(+)-α-Methylbenzylamine	IPA	210µL		solid formed after sonicator
7	N-Methyl-D-glucamine	IPA	Did not dissolve	20.70mg	solid formed on cooling
8	(1R 2S)-(+)-Thiomine	IPA	Did not dissolve	22.62mg	solid formed on cooling
9	N-Ethyl-D-glucamine	IPA	Did not dissolve	22.41mg	solid formed on cooling
10	(S)-(+)-2-Amino-1-propanol	IPA	210µL		solid formed on cooling
11	L-Arginine	Ethyl acetate	210µL		no solid produced
12	(R)-(-)-2-amino-1-butanol	Ethyl acetate	210µL		solid formed on cooling
13	(R)-(-)-1-amino-1-propanol	Ethyl acetate	210µL		solid formed on cooling
14	(R)-(-)-1-Cyclohexylethylamine	Ethyl acetate	210µL		solid formed on cooling
15	L-Lysine	Ethyl acetate	Did not dissolve	15.66mg	solid formed on cooling
16	(R)-(+)-α-Methylbenzylamine	Ethyl acetate	210µL		solid formed after sonicator
17	N-Methyl-D-glucamine	Ethyl acetate	Did not dissolve	20.70mg	solid formed on cooling
18	(1R 2S)-(+)-Thiomine	Ethyl acetate	Did not dissolve	22.62mg	solid formed on cooling
19	N-Ethyl-D-glucamine	Ethyl acetate	Did not dissolve	22.41mg	solid formed on cooling
20	(S)-(+)-2-Amino-1-propanol	Ethyl acetate	210µL		solid formed on cooling

- 30 -

[00114] The solids were vacuum filtered and analyzed by chiral HPLC, as were the liquors collected. The results show there are a few bases that can be used to separate the enantiomers. Only one, thiomicamine, separated the enantiomers giving an excess of Compound 1, the desired enantiomer, in the solid. Therefore, these bases can be used to
5 separate the enantiomers, however, thiomicamine has shown to be the only base to separate the enantiomers in both ethanol and ethyl acetate effectively and gives the desired enantiomer.

Methodology for Examples 3 to 15

10

X-Ray Powder Diffraction (XRPD)

Siemens D5000

XRPD patterns were collected on a Bruker AXS or Siemens D5000 diffractometer.

15 [00115] X-Ray Powder Diffraction patterns were collected on a Siemens D5000 diffractometer using $\text{CuK}\alpha$ radiation (40kV, 40mA), θ - θ goniometer, automatic divergence and receiving slits, a graphite secondary monochromator and a scintillation counter. The instrument was performance checked using a certified Corundum standard (NIST 1976).

20

Ambient conditions

[00116] Samples run under ambient conditions were prepared as flat plate specimens using powder as received. Approximately 35mg of the sample was gently packed into a cavity cut into polished, zero-background (510) silicon wafer. The sample
25 was rotated in its own plane during analysis. The details of the data collection are:

Angular range: 2 to 42° 2 θ

Step size: 0.05° 2 θ

Collection time: 4s.step-1

30 **Bruker AXS C2 GADDS**

[00117] X-Ray Powder Diffraction patterns were collected on a Bruker AXS C2 GADDS diffractometer using $\text{CuK}\alpha$ radiation (40kV, 40mA), automated XYZ stage,

- 31 -

laser video microscope for auto-sample positioning and a HiStar 2-dimensional area detector. X-ray optics consists of a single Göbel multilayer mirror coupled with a pinhole collimator of 0.3mm.

- 5 **[00118]** The beam divergence, i.e., the effective size of the X-ray beam on the sample, was approximately 4 mm. A θ - θ continuous scan mode was employed with a sample – detector distance of 20 cm which gives an effective 2θ range of $3.2^\circ - 29.7^\circ$. Typically the sample would be exposed to the X-ray beam for 120 seconds.

10 Ambient conditions

[00119] Samples run under ambient conditions were prepared as flat plate specimens using powder as received without grinding. Approximately 1-2mg of the sample was lightly pressed on a glass slide to obtain a flat surface.

15 Non-ambient conditions

[00120] Samples run under non-ambient conditions were mounted on a silicon wafer with heat conducting compound. The sample was then heated to the appropriate temperature at ca. $20^\circ\text{C}.\text{min}^{-1}$ and subsequently held isothermally for about 1 minute before data collection was initiated.

20

Single Crystal X-Ray Diffraction (SCXRD)

- [00121]** Data were collected on a Bruker AXS 1K SMART CCD diffractometer equipped with an Oxford Cryosystems Cryostream cooling device. Structures were solved using either the SHELXS or SHELXD programs and refined with the SHELXL
25 program as part of the Bruker AXS SHELXTL suite. Unless otherwise stated, hydrogen atoms attached to carbon were placed geometrically and allowed to refine with a riding isotropic displacement parameter. Hydrogen atoms attached to a heteroatom were located in a difference Fourier synthesis and were allowed to refine freely with an isotropic displacement parameter.

30

¹H NMR

[00122] NMR spectra were collected on a Bruker 400MHz spectrometer equipped with an auto-sampler. Samples were prepared in *d*₆-DMSO, unless otherwise stated.

5 *Solid State ¹³C NMR*

[00123] NMR Spectra were collected on a Bruker Avance DRX-200 spectrophotometer. Samples were spun at 5kHz in a 4mm Bruker SB magic-angle spinning probe for ¹³C NMR at 50.3 MHz. Samples were packed into 4mm Z_nO NMR rotors and sealed with Kell-F caps. Proton transmitter power was increased to a value
10 corresponding to a 90° pulse width of 2.8μs for proton decoupling during ¹³C data acquisition. Transients were averaged over 1h. Chemical shifts were referenced to an external reference using carbonyl resonance of glycine (176ppm).

Differential Scanning Colorimetry (DSC)

15 [00124] DSC data were collected on a TA Instruments Q1000 equipped with a 50 position autosampler. The instrument was calibrated for energy and temperature calibration using certified indium.

[00125] Typically 0.5-3 mg of each sample, in a pin-holed aluminium pan, was
20 heated at 10°C.min⁻¹ from 25°C to 250°C. A nitrogen purge at 30 mL.min⁻¹ was maintained over the sample.

Thermo-Gravimetric Analysis (TGA)

[00126] TGA data were collected on a TA Instruments Q500 TGA, equipped with a
25 16 position autosampler. The instrument was temperature calibrated using certified Alumel.

[00127] Typically 5-30 mg of each sample was loaded onto a pre-tared platinum crucible and aluminium DSC pan, and was heated at 10°C.min⁻¹ from ambient
30 temperature to 350°C. A nitrogen purge at 60 mL.min⁻¹ was maintained over the sample.

Gravimetric Vapour Sorption (GVS)

[00128] Sorption isotherms were obtained using a Hiden IGASorp moisture sorption analyzer, controlled by CFRSorp software. The sample temperature was maintained at 25°C by a Huber re-circulating water bath. The humidity was controlled by mixing streams of dry and wet nitrogen, with a total flow rate of 250 mL.min⁻¹. The relative humidity was measured by a calibrated Vaisala RH probe (dynamic range of 0-95%RH), located near the sample. The weight change, (mass relaxation) of the sample as a function of %RH was constantly monitored by the microbalance (accuracy ±0.001mg).

10 [00129] Typically 10-20 mg of sample was placed in a tared mesh stainless steel basket under ambient conditions. The sample was loaded and unloaded at 40%RH and 25°C (typical room conditions).

15 [00130] A moisture sorption isotherm was performed as outlined below (2 scans giving 1 complete cycle). The standard isotherm was performed at 25°C at 10% RH intervals over a 0-90% RH range. Parameters are shown in Table 6:

Table 6.

Parameters	Values
Adsorption - Scan 1	40 - 90
Desorption / Adsorption - Scan 2	85 - Dry, Dry - 40
Intervals (%RH)	10
Number of Scans	2
Flow rate (mL.min ⁻¹)	250
Temperature (°C)	25
Stability (°C.min ⁻¹)	0.05
Minimum Sorption Time (hours)	1
Maximum Sorption Time (hours)	4
Mode	AF2
Accuracy (%)	98

20 [00131] The software uses a least squares minimization procedure together with a model of the mass relaxation, to predict an asymptotic value. The measured mass relaxation value must be within 5% of that predicted by the software, before the next

- 34 -

%RH value is selected. The minimum equilibration time was set to 1 hour and the maximum to 4 hours.

5 **[00132]** The sample was recovered after completion of the isotherm and re-analyzed by XRPD.

Water Determination by Karl Fischer Coulometry (KF)

10 **[00133]** The water content of each sample was measured on a Mettler Toledo DL39 Coulometer using Hydranal Coulomat AG reagent and an argon purge. Weighed solid samples were introduced into the vessel on a platinum TGA pan which was connected to a subaseal to avoid water ingress. Approx 10 mg of sample was used per titration and duplicate determinations were made.

High Performance Liquid Chromatography (HPLC)

15 **Purity Determination**

[00134] Purity analysis was performed on an Agilent HP1100 series system equipped with a diode array detector and using ChemStation software v9. Methods are shown in Tables 7 and 8.

20 Table 7.

Type of method	Normal Phase	Reverse Phase		x
	Isocratic	Gradient		x
Column:	Phenomenex Luna C18 (2), 150 x 4.6mm, 5µm			
Column Temperature (°C):	25			
Injection (µL):	10			
Detection: Wavelength, Bandwidth(nm):	255, 90 nm bandwidth			
Flow Rate (mL.min-1):	1.0			
Phase A:	0.1% TFA in water			
Phase B:	0.085% TFA in acetonitrile			
Timetable:	Time (min)	% Phase A	% Phase B	
	0	95	5	
	25	5	95	
	25.2	95	5	

- 35 -

	30	95	5
--	----	----	---

Table 8. Chiral analysis

Type of method	Normal Phase		Reverse Phase	x
	Isocratic		Gradient	x
Column:	Regis Technologies (S,S)-Whelk-01 10/100 Kromasil FEC 250 x 4.6mm			
Column Temperature (°C):	20			
Injection (µL):	10			
Detection:	UV at 220nm			
Wavelength, Bandwidth (nm):				
Flow Rate (mL.min ⁻¹):	2.0			
Mobile phase:	60:40:0.1 n-Hexane: Ethanol : Acetic acid			
Sample solvent:	60:40 n-Hexane : Ethanol			

Ion Chromatography

- 5 **[00135]** Data were collected on a Metrohm 861 Advanced Compact IC using IC Net software v2.3. Samples were prepared as 1000 ppm stocks in water. Where sample solubility was low, a suitable solvent such as DMSO was used. Samples were diluted to 50 ppm or 100 ppm with an appropriate solvent prior to testing. Quantification was achieved by comparison with standard solutions of known concentration of the ion being
- 10 analyzed. Conditions are shown in Tables 9A and 9B.

Table 9A.

Type of method	Anion exchange
Column:	Metrosep A Supp 5 – 250 (4.0x250mm)
Column Temperature (°C):	Ambient
Injection (µL):	20
Detection:	Conductivity detector
Flow Rate (mL.min ⁻¹):	0.7
Eluent:	3.2mM sodium carbonate, 1.0mM sodium hydrogen carbonate in water

Table 9B.

Type of method	Cation exchange
Column:	Metrosep C 2 – 250 (4.0x250mm)

- 36 -

Column Temperature (°C):	Ambient
Injection (μL):	20
Detection:	Conductivity detector
Flow Rate (mL.min ⁻¹):	1.0
Eluent:	4.0mM Tartaric acid, 0.75mM Dipicolinic acid in water

Example 3: Salt Selection

[00136] Compound 1 was dissolved in the solvent *iso*-propanol (IPA) or tetrahydrofuran (THF) as stated in Table 10 and had 1.05 molar equivalents of the pharmaceutically acceptable base added. The bases were prepared in a one molar solution, unless the base would not dissolve, in which case it was added as a solid. All solutions had 1.05 molar equivalents of the base added to them.

[00137] The solutions were stirred at 50°C for two hours, and then cooled to 5°C over three and a half hours with continued stirring. The samples were then stored at 5°C for three days. Those that were still in solution were sonicated for ten minutes, and then if that gave no solids, the solvent was allowed to evaporate off slowly. All solids collected were analyzed by XRPD. The results are shown in Table 10.

Table 10. Results of the initial salt selection.

Sample	Base	Solvent	Conc. and volume of solution used	Mass used	Cooling to 5°C	Sonicated	Evaporated
1	Potassium hydroxide	IPA	24.3µL of 1M		No solid	No solid	Gum
2	Sodium hydroxide	IPA	24.3µL of 1M		No solid	No solid	Gum
3	L-Arginine	IPA	48.7µL of 0.5M		No solid	No solid	Gum
4	Choline	IPA	24.3µL of 1M		No solid	No solid	Gum
5	L-Lysine monohydrate	IPA	Added as solid	4.00mg	Crystalline	-	-
6	Dimethylaminoethanol	IPA	24.3µL of 1M		No solid	No solid	Gum
7	N-Ethylglucamine	IPA	Added as solid	5.09mg	Amorphous	-	-
8	N-Methylglucamine	IPA	Added as solid	4.75mg	Amorphous	-	-
9	Tromethamine	IPA	Added as solid	2.95mg	Crystalline	-	-
10	Potassium hydroxide	THF	24.3µL of 1M		No solid	No solid	Gum
11	Sodium hydroxide	THF	24.3µL of 1M		No solid	No solid	Gum
12	L-Arginine	THF	48.7µL of 0.5M		No solid	No solid	Gum
13	Choline	THF	24.3µL of 1M		No solid	No solid	Gum
14	L-Lysine monohydrate	THF	Added as solid	4.00mg	Crystalline	-	-
15	Dimethylaminoethanol	THF	24.3µL of 1M		No solid	No solid	Gum
16	N-Ethylglucamine	THF	Added as solid	5.09mg	No solid	No solid	Gum
17	N-Methylglucamine	THF	Added as solid	4.75mg	No solid	No solid	Gum
18	Tromethamine	THF	Added as solid	2.95mg	No solid	No solid	Gum

[00138] Only three of the samples gave any solid crystalline material. The lysine salt from IPA and THF and the tromethamine salt from IPA. The XRPD analysis shows these all have different crystalline patterns. The HPLC chemical purity analysis of the lysine and tromethamine salts shows an improvement in the purity from the starting material, from 96.7% to 98.0% for the lysine salt and 97.8% for the tromethamine salt.

[00139] The crystalline lysine salt was shown to deliquesce at 40°C / 75% RH and 25°C / 94% RH. The tromethamine salt deliquesced at 25°C / 94% RH. As a result, neither of these amine salts were suitable for pharmaceutical development.

10

Example 4: Further Salt Selection

[00140] The attempts to make a salt with potassium or sodium were repeated with different solvents. 20 mg of Compound 1 was dissolved in 20 µL of the appropriate solvent, to which 1.05 molar equivalents of potassium hydroxide or sodium hydroxide was added as a one molar solution in water. The solutions were heated to 50°C for two hours and cooled to 5°C over 21 hours, stirring throughout. If no solids formed after cooling the solutions were sonicated, then if still no solid formed, the solvent was allowed to evaporate to try to crystallize the salt.

20 Table 11 – Results of the potassium/sodium salt formation

Sample	Base	Solvent	Cooling to 5°C	Sonicated	Evaporated
1	Potassium hydroxide	Ethyl acetate	No solid	No solid	Gum
2	Potassium hydroxide	Acetonitrile	No solid	No solid	Gum
3	Potassium hydroxide	Dioxane	No solid	No solid	Gum
4	Potassium hydroxide	Toluene	No solid	No solid	Gum
5	Potassium hydroxide	DCM	No solid	No solid	Gum
6	Sodium hydroxide	Ethyl acetate	No solid	No solid	Gum
7	Sodium hydroxide	Acetonitrile	No solid	No solid	Gum
8	Sodium hydroxide	Dioxane	No solid	No solid	Gum
9	Sodium hydroxide	Toluene	No solid	No solid	Gum
10	Sodium hydroxide	DCM	No solid	No solid	Gum

There was no solvent in which the solution gave a solid, only gums were produced.

[00141] The gums were used to slurry in a new set of solvents in an attempt to generate crystalline material. 100 μ L of the solvent was added to the gum and put for maturation overnight on a cycle between 50°C for four hours, then room temperature for four hours. Any solids were filtered and analyzed by XRPD. The results are shown in Table 12.

Table 12. Results of the slurring of potassium/sodium salts.

Sample	Base	Solvent	After maturation
1	Potassium hydroxide	Acetone	No solid
2	Potassium hydroxide	IPA	No solid
3	Potassium hydroxide	THF	No solid
4	Potassium hydroxide	Ethanol	No solid
5	Sodium hydroxide	Acetone	No solid
6	Sodium hydroxide	IPA	Crystalline solid
7	Sodium hydroxide	THF	No solid
8	Sodium hydroxide	Ethanol	Crystalline solid

[00142] The solids from IPA and ethanol gave new crystalline patterns from the XRPD analysis. The XRPD peaks and their intensities are shown in Tables 13 and 14.

Table 13. XRPD peaks for Compound 4.

Angle 2 θ	Intensity %
5.5	40.1
6.7	9.9
8.0	100.0
8.7	42.4
9.3	35.7
11.1	6.2
13.4	79.4
14.3	14.6
14.7	7.8
15.8	11.7
16.1	20.0

- 40 -

Angle 2 θ	Intensity %
16.6	11.7
17.4	48.5
17.8	17.2
18.8	35.7
20.3	16.9
20.9	20.1
21.4	24.9
22.2	27.0
22.8	23.5
24.2	22.7
25.4	22.9
26.9	15.8
27.6	9.5
28.7	10.0
29.7	17.6
30.3	13.1
31.3	12.3
32.1	12.4
33.5	10.7
35.7	16.8
41.0	12.8

Table 14. XRPD peaks for Compound 5.

Angle 2 θ	Intensity %
5.4	38.1
6.6	12.0
7.9	100.0
8.6	40.6
9.2	25.1
10.8	13.8
13.4	68.0
14.0	20.0
15.9	42.1
16.4	25.9
17.3	70.1

- 41 -

Angle 2 θ	Intensity %
17.6	48.7
18.6	93.5
20.0	78.1
20.5	63.1
21.1	53.8
21.9	94.2
22.5	53.6
23.0	35.9
24.0	57.7
25.0	81.2
25.5	38.8
26.0	39.1
26.6	53.4
27.2	27.1
28.3	20.6
29.3	21.5

[00143] Analysis by ion chromatography showed the solid to contain one mole of sodium. ¹H NMR confirmed the presence of solvent and chiral HPLC analysis show that no significant degradation had occurred and it was still the pure enantiomer Compound

- 5 1. When analyzed by variable temperature XRPD, the crystal structure broke down after heating above 135°C. Attempts to make the sodium salt in IPA and ethanol by slow cooling, seeding, evaporation of solvent and maturation all failed. The sodium salt solvates were placed at 40°C/75% RH for one week, which gave a new XRPD trace, identified as a trihydrate by a 10% weight loss on the TGA, equating to three moles of
- 10 water, and the removal of the solvent, either ethanol or IPA.

Example 5: Sodium Salt Studies

- [00144] In an attempt to form the sodium salt ethanol solvate directly, Compound 4, without crystallization from a gum, the salt was prepared using sodium ethoxide in
- 15 ethanol instead of using sodium hydroxide in water. It was thought that the presence of water in the initial preparation may have prevented crystallization.

- 42 -

[00145] 25mg of Compound 1 was dissolved in 50μL ethanol at room temperature. 18.4μL, 1.0 equivalent, of sodium ethoxide (21% in ethanol). Solid material rapidly crystallized on standing at room temperature. The sample filtered under vacuum and dried at 25°C under vacuum for one day. The XRPD and TGA analysis shows the material produced is the mono-ethanol solvate (Compound 4). This material was stored at 40°C/75% RH overnight forming the hydrate (Compound 6), for further analysis.

10

[00146] The hydrate, Compound 6, was identified again by XRPD. The XRPD peaks and their intensities are shown in Table 15.

Table 15. XRPD peaks for Compound 6.

Angle 2θ	Intensity %
4.8	95.1
5.5	14.4
7.3	29.5
8.3	21.3
9.9	35.4
12.0	43.3
12.6	44.1
15.2	63.7
16.7	100
17.2	92.6
17.9	61.3
19.0	76.8
21.5	62.3
23.5	66.4
24.5	66.1

15

[00147] When analyzed by variable temperature XRPD, the material lost crystallinity when heated above 70°C.

[00148] The GVS analysis of Compound 6 showed the material was losing some weight, 2%, before the analysis started, when stored at 40% RH. The weight increased gradually to +6% weight when taken up to 90% RH, then lost again when taken down to

- 43 -

- 0% RH, reaching -12% weight. On returning to 40% RH, the material reached -6% weight. This cycle of gradually increasing in weight to +6% by 90% RH, then dropping to -12% at 0% RH and ending at -6% weight at 40% RH was repeated. There were no plateaus where the weight was stable at a range of humidities. The GVS pattern suggests the water may be able to enter or leave the crystal lattice depending on the relative humidity of the atmosphere around it, giving a percentage water content for the specific relative humidity of the atmosphere in which the material is contained. So, if the humidity is higher, at 75% RH, Compound 6, was formed, however, when the humidity is lower, at 40% RH, Compound 7, was formed. The estimation of a dihydrate when removed from the GVS at 40% RH is supported by the TGA thermogram giving a weight loss of 6.6%, equating to two moles of water. The XRPD trace after GVS analysis matched the trace of the material before GVS analysis, so the transfer of water between the crystal and the atmosphere has not altered the crystal structure.
- 15 **[00149]** A sample of Compound 6 removed from 40°C / 75% RH was dried at 40°C, with no vacuum, for four days. This material gave the same XRPD trace after drying, but when analyzed by TGA, the material showed a weight loss of 6.6%, again giving us the dihydrate, Compound 7. This supports the GVS as the material was stored at 40°C, but still at the ambient relative humidity of 40%. Four moles of water is 12.3% by weight, 20 three moles is 9.25% and two moles is 6.2%. The XRPD peaks and intensities for Compound 7 are shown in Table 16.

Table 16. XRPD peaks for Compound 7.

Angle 2 θ	Intensity %
4.8	100.0
5.5	17.5
7.3	23.7
8.2	16.9
12.1	71.4
12.8	25.3
15.8	75.1
16.9	95.0

- 44 -

18.2	86.2
19.3	84.8
25.6	61.7

[00150] Subsequent DSC-TGA analysis of Compound 6 gave a 13% weight loss suggesting that Compound 6 may have 4 molecules of water or 4+ fractional molecules of water. Subsequent DSC-TGA analysis of Compound 7 gave a 5.5% weight loss suggesting that Compound 7 may be a fractional hydrate with less than 2 molecules of water. In these subsequent DSC-TGA studies, the data was obtained on a SDT Q600 Instrument starting at ambient temperature and increasing to about 300°C at 10°C per minute.

10 **Example 6: Sodium Salt Hydrates**

[00151] The sodium salt hydrate was prepared only by exposure to high humidities, so a series of experiments were set up to convert the sodium salt solvates to the hydrate by means of crystallizing the hydrate from solution.

15 [00152] The IPA and ethanol solvates of the salt were slurried in water, using 25mg of the salt in 100µL of water, slurried at 25°C, which recrystallized a material giving a new trace by XRPD of 99.1% chemical purity when analyzed by HPLC. The TGA analysis showed a weight loss of 25%, which began losing weight immediately when heating started. Ion chromatography showed the new crystal formed was a hemi-sodium salt. This material is less favourable than the previous hydrate observed, so continued effort was made to form the previous hydrate by slurrying. The XRPD peaks and intensities for the hemi-sodium salt hydrate are shown in Table 17.

Table 17. XRPD peaks for hemi sodium salt hydrate

Angle 2θ	Intensity %
6.2	9.2
7.8	15.6
8.7	13.6
10.1	26.0

- 45 -

Angle 2 θ	Intensity %
12.1	21.8
12.7	22.8
13.7	24.8
15.6	43.4
16.1	28.9
16.9	27.2
18.5	44.9
19.8	48.3
20.9	60.5
21.3	50.7
22.4	62.6
23.4	69.5
24.4	100.0
25.1	79.6
25.5	69.0
26.3	75.3

[00153] The ethanol solvate of the sodium salt was used to try to form the hydrate by slurrying in ethanol or IPA with varying proportions of water.

- 5 [00154] The precipitates formed from slurries in 75% water solutions, gave the same XRPD trace as the material that was slurried in 100% water, giving the hemi-sodium salt. One sample that gave a new crystalline XRPD pattern and was slurried in 10% water in ethanol. This sample was sent for single crystal analysis, which proved the material to be a hemi-sodium salt mono-ethanolate.

10

- [00155] Another attempt was made to form the hydrated sodium salt from the ethanol solvate of the sodium salt. 25mg of the ethanol solvate of sodium salt, Compound 4, was weighed into each vial, to which the appropriate solvent containing 1% water was added. The solvent was added 10 μ L at a time to ensure the material made a slurry, before being placed in the maturation chamber, cycling four hours at 50°C and
15 four hours at room temperature. The samples were seeded with the previously formed hydrated sodium salt. If no solid formed when retrieved from the maturation chamber

they were stored at 5°C to encourage crystallization. If there was no solid after three days at 5°C, the anti-solvent, heptane, was added drop-wise and the solutions placed back into the maturation chamber. The results are shown in Table 18.

5 Table 18. Results of slurring in 1% aqueous solutions.

Sample	Solvent	Volume of solvent used	After maturation	Stored at 5°C	Anti-solvent added
1	Acetone	30µL	No solid	No solid	Crystalline solid matching ethanol solvate
2	THF	30µL	No solid	No solid	Crystalline solid matching ethanol solvate
3	Acetonitrile	30µL	No solid	No solid	Gum
4	MIBK	30µL	Gum	n/a	n/a
5	MEK	30µL	Crystalline solid matching MEK solvate	n/a	n/a
6	Ethyl acetate	40µL	Crystalline solid matching ethanol solvate	n/a	n/a
7	Dioxane	70µL	No solid	Crystalline solid not the hydrate	n/a

10 [00156] The material collected was filtered and analyzed by XRPD. The sample from methylethylketone (MEK) gave a diffractogram not previously seen and so likely to be the MEK solvate. The sample from ethyl acetate, THF and acetone gave the XRPD diffractogram pattern matching the ethanol solvate starting material. The material collected from dioxane gave a new trace, not seen previously, so is likely to be a dioxane solvate. The remaining two samples gave only gums.

Example 7: Polymorphism of the Mono-Sodium Salt (Compound 2)

15 [00157] Approximately 30 mg of the mono-ethanolate sodium salt (Compound 4) was added to each of fifteen vials. 200µL of the appropriate solvent was added, noting the solubility at room temperature. If the material dissolved fully it was placed at 5°C, if not fully dissolved, was placed at 50°C. All vials were then stored at 5°C for 16 hours. The solutions that gave a solid were analyzed by XRPD, those that remained a solution

- 47 -

were allowed to evaporate slowly at ambient conditions. The results are shown in Table 19.

Table 19. Results of the polymorphism screen.

Expt No.	Solvent	water content added	weight (mg)	Solubility at 25°C in 200µL	Solubility at 50°C	Solubility at 5°C after 16hrs	After Evaporation
1	Acetone	10%	30	✓	n/a	solution	
2	Ethanol	10%	33	✓	n/a	solution	
3	THF	10%	33	✓	n/a	solution	
4	MeCN	10%	34	✓	n/a	solution	
5	MEK	10%	30	✓	n/a	solution	
6	1-propanol	10%	33	✓	n/a	solution	
7	EtOAc	10%	31	✓	n/a	ppte	n/a
8	Acetone	-	32	✓	n/a	solution	gum
9	THF	-	34	✓	n/a	solution	gum
10	MeCN	-	33	✓	n/a	solution	ppte
11	MEK	-	32	✓	n/a	ppte	n/a
12	1-propanol	-	33	x (slurry)	x (slurry)	ppte	n/a
13	EtOAc	-	34	x (slurry)	✓	ppte	n/a
14	TBME	-	32	x (slurry)	x (slurry)	ppte	n/a
15	heptane	-	34	x (slurry)	x (slurry)	ppte	n/a

5

[00158] Seven of the samples, Samples 7, 10, 11, 12, 13, 14 and 15, gave a solid, which were analyzed by XRPD. The XRPD diffractograms of these seven samples gave three new patterns from acetonitrile, MEK and 100% EtOAc, which had a matching pattern to the sample from tert-butylmethylketone (TBME). The samples from heptane and 1-propanol gave the same pattern as the ethanol solvate and the sample from 10% water in EtOAc gave the same pattern as the hemi-sodium salt. Samples 10, 11, 13 and 14 were dried at 25°C under vacuum for one hour, then analyzed by ¹H NMR, which showed Sample 10 retained minimal solvent indicating it to be a crystalline non-solvated form of the sodium salt. This sample was investigated further, being analyzed by GVS, TGA, DSC and all four of these samples being stored at 40°C / 75% RH, followed by

15

- 48 -

further XRPD analysis. The XRPD peaks and intensities for the non-solvated sodium salt (Compound 2) are shown in Table 20.

Table 20. XRPD peaks for Compound 2.

Angle (2-theta)	Intensity %
5.5	49.1
6.0	18.6
6.9	7.4
8.5	10.0
9.6	34.0
11.0	57.7
13.3	38.9
14.0	16.2
16.1	18.7
16.7	35.8
17.9	28.1
18.4	57.1
19.6	29.3
20.6	100.0
21.8	29.4
22.3	39.1
23.3	27.1
23.9	23.3

5

[00159] The material from acetonitrile (MeCN) showed a weight loss of 3.5% on the TGA, which was lost gradually until about 120°C, when the weight was lost more rapidly, coinciding with an endotherm observed from the DSC representing the melting of the crystalline form. The GVS analysis showed a rise in weight of about 17% from 40% RH to 90% RH, which then dropped to a weight of -2% at 0% RH, dropping a total of 19% weight. The weight gained 6% by 40% RH, matching the weight increase observed from the hydrate, not returning to the weight of the material as it entered. The repeated cycle matched that of the cycle of the hydrate and the XRPD diffractogram of the material after GVS analysis showed it to be the hydrated form of the salt. This was

10

observed as well by the XRPD diffractogram of the other three samples after they were stored at 40 / 75% RH.

Example 8: Potassium Salt of Compound 1

- 5 **[00160]** The procedure for forming the sodium salt, using sodium ethoxide, was repeated using potassium ethoxide. 25mg of the amorphous free acid, Compound 1, was dissolved in 50 μ L ethanol. 22 μ L of potassium ethoxide (24% in ethanol), one molar equivalent, was added and the solution stored in a shaker at 25°C for three days. With no solid precipitating, the vial was placed in a sonicator for five minutes, then stored at 5°C
- 10 to try to induce crystallization of a potassium salt. This was repeated, using a range of different solvents to dissolve the free acid. The results are shown in Table 21.

Table 21. Results of the potassium salt formation.

Sample	Solvent	Storage in the shaker at 25°C	Sonication	Stored at 5°C	Maturation with anti-solvent
1	Methanol	No solid	No solid	No solid	Oil
2	IPA	No solid	No solid	No solid	Gum
3	THF	No solid	No solid	No solid	Gum
4	Ethyl acetate	No solid	No solid	No solid	Gum
5	Acetonitrile	No solid	No solid	No solid	Oil
6	Dioxane	No solid	No solid	No solid	Gum
7	Toluene	No solid	No solid	No solid	Amorphous
8	DCM	No solid	No solid	No solid	Gum
9	Acetone	No solid	No solid	No solid	Gum
10	Water	No solid	No solid	No solid	Oil

- 15 **[00161]** None of the solvents used gave a precipitate throughout the experiments. In a further attempt to try to get the potassium salt to crystallize, the solvent was allowed to evaporate slowly, giving only gums from all the samples. The gums were re-dissolved in 200 μ L of the same solvent at 50°C, then heptane, the anti-solvent, was added drop-wise to give some precipitate, which was then stored in a maturation chamber, cycling
- 20 between 50°C for four hours and room temperature for four hours. All of the samples

- 50 -

5 filtered to give gums or oils, except for one sample from toluene, which, when analyzed by XRPD, gave an amorphous curve, but with small peaks within it. The sample from toluene had 50 μ L of toluene added to it and was returned to the maturation chamber for an extra four days, after which time the sample was re-analyzed by XRPD, showing a slight improvement of the peaks on the diffractogram, but was still mainly amorphous.

10 [00162] To investigate the sample from toluene, the salt formation was repeated on a larger scale. 50 mg of the free acid, Compound 1, (purified via the sodium salt) was dissolved in 400 μ L of toluene, to which 44 μ L of potassium ethoxide (24% weight in ethanol) was added. Heptane was added drop-wise to the solution until some precipitate was observed and the vial was placed in the maturation chamber, cycling between 50°C for four hours and room temperature for four hours. The material collected was filtered, but formed a gum on standing.

15 **Example 9: Calcium and Magnesium Salts of Compound 1**

[00163] The mono-ethanolate sodium salt of Compound 2 was used in an attempt to exchange the sodium ion with a calcium or a magnesium ion. 50 mg of the sodium salt was dissolved in an IPA/water mixture. 5.47 mg of calcium chloride and 4.70 mg of magnesium chloride were dissolved in 11 mL and 9 mL of methanol respectively. The calcium chloride solution and the magnesium chloride solution were each added to a solution of 50 mg of the sodium salt and stirred for three hours, then stored at 5°C overnight.

25 [00164] The solution was placed on the rotary evaporator to remove the solvent, leaving a solid. Water was added to remove any sodium chloride that may have been present and the material was filtered.

30 [00165] The magnesium sample gave a gum, but the calcium sample gave an amorphous solid, by XRPD analysis. This was analyzed by ^1H NMR and ion chromatography. The ^1H NMR showed the same peaks as previously observed for the free acid. The ion chromatography results show the material only contained 0.07

equivalents of the calcium ion in the sample, which should have been 0.5 if the calcium salt had formed. The amorphous material must have been the amorphous free acid Compound 1 with a minimal amount of calcium chloride remaining in the sample as a mixture.

5

Example 10: Conversion of Sodium Salt to Free Acid

[00166] Amorphous Compound 2 (5.00 g, 8.59 mmol) was dissolved in ethyl acetate (50 mL) and washed with 1M HCl (30 mL), dried with MgSO₄ and evaporated to give a yellow foam. this foam was dried under high vacuum at 50°C for 2 hours giving 4.373 g yellow foam (100%). Integration of the signals at δ 1.25, 2.39 and 2.87 in the ¹H NMR spectrum suggested 2.6% w/w ethyl acetate remained trapped in the foam. HPLC analysis shows a purity of 97.1%. Chiral HPLC indicates the sample is in >98% enantiomeric excess.

15 [00167] m/z (ES⁻) 506.2 [MH⁺, 100%], 507.2 [¹³C-MH⁺, 40%]; HRMS C₃₂H₂₈NO₅ requires 506.1967, found 506.1964. ¹H NMR (CDCl₃, 500 MHz) δ 2.39 (1H*, dd, *J* 16.3, 6.0), 2.87 (1H, dd, *J* 16.3, 6.2), 3.32 (1H, dd, *J* 16.2, 4.8), 3.39 (1H* dd, *J* 16.2, 2.4), 3.81 (3H*, s), 3.81 (3H, s), 4.42 (1H, d, *J* 14.9), 4.49 (1H*, d, *J* 17.2), 4.58 (1H, d, *J* 14.9), 4.82 (2H*, m), 4.89 (1H, d, *J* 10.9), 4.95 (2H*, m), 5.01 (1H, d, *J* 11.0), 5.15 (1H, 20 1H*, m), 5.31 (1H, s), 6.54 (1H, d, *J* 8.4), 6.70 (1H, d, *J* 8.4), 6.78 (1H*, d, *J* 8.5), 6.84 (1H*, d, *J* 8.5), 7.10-7.41 (15H, 15H*, m). ¹³C NMR (CDCl₃, 125 MHz) 24.9, 25.8*, 43.3*, 45.6, 52.4, 54.4*, 55.5, 55.6*, 55.9, 60.4*, 74.8*, 74.9, 111.2, 111.7*, 121.4, 122.2*, 125.3, 125.6, 125.7, 127.0, 127.1, 127.2, 127.2, 127.4, 128.0, 128.2, 128.3, 128.4, 128.5, 128.6, 128.6, 128.6, 128.8, 129.0, 129.1, 129.2, 129.4, 137.4, 137.6*, 25 138.3*, 138.8, 138.9, 139.2*, 145.0, 151.1*, 151.8, 171.9*, 172.5, 175.4, 175.5. [α]_D +5.1 (DCM, c0.68); IR (cm⁻¹, KBr disc), 3439, 3029, 1737, 1621, 1496, 1454, 1275, 1215, 1093, 1050, 895, 803, 747, 700, 632. * denotes minor rotamer.

Example 11: Recrystallization of Free Acid

30 [00168] The free acid (Compound 1) formed in Example 10 was added to ten vials, 25 mg in each, to which 15 μ L of the appropriate solvent was added and placed in a

maturation chamber cycling four hours at 50°C and four hours at room temperature for three days. After this time, those that did not recrystallize were sonicated, then if still no solid formed, were stored at 5°C. The results are shown in Table 22.

5 Table 22. Results of the recrystallization of the free acid.

Sample	Solvent	Slurrying over three days	Sonication	Stored at 5°C	Maturation with anti-solvent
1	Ethanol	No solid	No solid	No solid	Gum
2	IPA	No solid	No solid	No solid	Gum
3	THF	No solid	No solid	No solid	Gum
4	Ethyl acetate	No solid	No solid	No solid	Gum
5	Acetonitrile	No solid	No solid	No solid	Oil
6	Dioxane	No solid	No solid	No solid	Gum
7	Toluene	No solid	No solid	No solid	Gum
8	DCM	No solid	No solid	No solid	Gum
9	Acetone	No solid	No solid	No solid	Oil
10	Water	No solid	No solid	No solid	Amorphous

[00169] None of the solutions recrystallized any solid material, so the solvents were allowed to evaporate slowly, however, this gave only gums. 200 µL of the same solvent was added to each vial and heated to 50°C to dissolve the gum. Heptane was added to the solution until some precipitate was observed, then the vial was placed in the maturation chamber. All of the samples gave either a gum or an oil, except for one, from water, which gave an amorphous solid when analyzed by XRPD.

Example 12: Attempted Recrystallization of Free Acid from Sodium Salt

15 [00170] A procedure to prepare an amorphous form of Compound 1 from the α -methylbenzylamine salt is described in US Patent No. 5,246,943 (1992) which involves the addition of aqueous potassium bisulphate solution to a methanol solution of the α -methylbenzylamine salt of Compound 1. This technique of preparing the free acid form of Compound 1 by precipitation with potassium bisulphate solution was used in an attempt to characterize the physical form of the resulting free acid when this technique

- 53 -

was applied to the sodium salt (Compound 2). 50 mg of the sodium salt was dissolved in a minimum volume of methanol and a solution of potassium bisulfate, in methanol (excess of 1% potassium bisulfate), was added drop-wise to precipitate the free acid. The vial was placed in the maturation chamber, alternating between 50°C and room temperature for four hours each, for three days. The sample was filtered and the XRPD diffractogram showed the material collected was amorphous; however, there were some peaks in the diffractogram caused by some of the remaining inorganic material.

Example 13: Stability of Ethanol Solvate to Varying Humidity

10 **[00171]** A sample of the ethanol solvate was placed at 40°C/75% RH overnight to form the sodium salt trihydrate. This conversion was checked by XRPD before proceeding to use the hydrated form. About 600 mg was prepared.

15 **[00172]** The material was split into six batches of 90 mg and stored at six different temperatures and humidities. The humidities were fixed by storing the material in a container above a saturated solution of one of potassium acetate, potassium carbonate or sodium nitrite stored at either 40°C or 25°C. This gives the six temperature and humidity conditions stated in Table 23 below. The material was analyzed by XRPD, HPLC and coulometric Karl Fischer after one, seven and fourteen days.

Table 23. Results of the humidity stability assessment.

Sample	Saturated solution	Temp	Relative humidity	One day			Seven days			14 days		
				XRPD	HPLC	Karl Fischer	XRPD	HPLC	Karl Fischer	XRPD	HPLC	Karl Fischer
1	Potassium acetate	25°C	22%	Slight change in peaks (2)	97.7%	7.6%	No change from prev. (2)	96.2%	10.2%	No change from prev. (2)	97.6%	9.5%
2	Potassium acetate	40°C	20%	Slight change in peaks (2)	97.7%	6.7%	No change from prev. (2)	97.1%	8.7%	No change from prev. (2)	97.8%	8.1%
3	Potassium carbonate	25°C	43%	No change (1)	97.9%	13.0%	No change (1)	97.7%	14.2%	No change (1)	96.8%	13.5%
4	Potassium carbonate	40°C	42%	No change (1)	97.3%	10.6%	Slight change in peaks (2)	97.5%	13.1%	No change from prev. (2)	97.5%	9.4%
5	Sodium nitrite	25°C	65%	No change (1)	97.0%	15.4%	No change (1)	97.0%	14.1%	No change (1)		*11.6%, 24.6%
6	Sodium nitrite	40°C	62%	No change (1)	97.7%	16.9%	No change (1)	97.3%	14.8%	No change (1)		14.9%

* - The coulometric Karl Fischer analysis gave a different result on the second run, so both results are displayed instead of a mean figure.

- 55 -

[00173] The material was made into the hydrate by storing at 40°C / 75% RH, so those stored at the lower humidity, about 60% RH remained the same material, without any changes in the XRPD diffractogram, keeping a high value of water content throughout. The material stored at the low humidities, around 20% RH, dropped in water content overnight, giving a slight change in one of the peaks on the XRPD diffractogram. One peak at 12 2-theta went from being a double peak to having a single peak. This difference in the XRPD diffractogram was apparent in all the material that lost water content. The material stored at about 40% RH lost water only when heated at 40°C over a week. At 25°C however, the water content, and therefore the XRPD diffractogram, remained the same throughout the two weeks. The purity of the material was maintained throughout the experiment and does not seem to be effected by storage at low or high humidities.

Example 14: Compound 2 Solubility and Stability

- [00174] Solubility of Compound 2 in a solvent, selected from water, methanol, acetonitrile (ACN) and *iso*-propanol and in 50 mM phosphate buffer at pH 1, 2, 7 and 8, 50 mM citrate buffer at pH 3, 4, 5 and 6 and in 50 mM borate buffer at pH 9 was assessed.
- [00175] Compound 2 was added to 10 mL of the solvent or buffer until the solution was visibly saturated and remained cloudy upon vortex mixing. Each sample was placed on a reciprocal shaker at room temperature for 24 hours then filtered through a 0.45 µm nylon filter to remove excess suspended compound.
- [00176] The samples were then diluted where required in accordance with Table 24, and analyzed by HPLC. The results were compared with a standard curve of known concentrations in ACN. The results are shown in Table 25.

Table 24. Stock Sample Dilutions for t=0 and t=1 week.

Sample	Volume of Stock Solution (mL)	Total Volume of Selected Media (mL)
H ₂ O	1	50

- 56 -

Sample	Volume of Stock Solution (mL)	Total Volume of Selected Media (mL)
H ₂ O	1	25
MeOH	1	100
ACN	1	25
IPA	1	25
pH 1	N/A	N/A
pH 2	N/A	N/A
pH 3	N/A	N/A
pH 4	N/A	N/A
pH 5	N/A	N/A
pH 6	1	10
pH 7	1	10
pH 8	1	10
pH 9	1	10

Table 25. Compound 2 Solution Solubility

Solvent	Solubility
pH 1 buffer (phosphate, 50 mM)	< 1 µg/mL
pH 2 buffer (phosphate, 50 mM)	< 1 µg/mL
pH 3 buffer (phosphate, 50 mM)	< 1 µg/mL
pH 4 buffer (citrate, 50 mM)	< 1 µg/mL
pH 5 buffer (citrate, 50 mM)	33 µg/mL
pH 6 buffer (citrate, 50 mM)	0.9 mg/mL
pH 7 buffer (phosphate, 50 mM)	1.7 mg/mL
pH 8 buffer (phosphate, 50 mM)	1.6 mg/mL
pH 9 buffer (borate, 50 mM)	5.3 mg/mL
Water	14 mg/mL
Methanol	> 50 mg/mL
Acetonitrile	12 mg/mL
IPA	0.7 mg/mL

[00177] The above analysis was taken as t=0 and the samples were then divided in two and one of each sample was stored at 5°C for one week and the other of each sample was stored at 25°C/60% relative humidity (RH) for one week.

- 57 -

[00178] After one week, the samples were allowed to equilibrate to room temperature and if required (H₂O and pH 7-9 samples stored at 5°C) refiltered to remove precipitate.

- 5 [00179] The samples were reanalyzed by HPLC. The results are shown in Tables 26 and 27.

Table 26. Compound 2 Solution Stability at 25°C/60%RH

Sample	% Purity		
	Initial % Purity	t=1 week % Purity at 25°C/60%RH	Δ% Purity at 25°C/60% RH
H ₂ O	95.58	95.67	+0.09
MeOH	97.39	97.39	0.00
ACN	97.50	97.46	-0.04
IPA	89.28	90.51	+1.23
pH 1*	-	-	-
pH 2*	-	-	-
pH 3*	-	-	-
pH 4*	-	-	-
pH 5*	-	-	-
pH 6	88.37	88.98	+0.61
pH 7	76.12	76.52	+0.40
pH 8	85.54	86.70	+1.16
pH 9	91.24	91.60	+0.36

*Due to the low solubility of the pH 1-5 solutions, no stability data could be determined

10

Table 27. Compound 2 Solution Stability at 5°C

Sample	% Purity		
	Initial % Purity	t=1 week % Purity at 5°C	Δ% Purity at 5°C
H ₂ O	95.58	94.66	-0.92
MeOH	97.39	97.52	+0.13
ACN	97.50	97.50	0.00
IPA	89.28	89.59	+0.31
pH 1*	-	-	-
pH 2*	-	-	-
pH 3*	-	-	-

- 58 -

pH 4*	-	-	-
pH 5*	-	-	-
pH 6	88.37	87.02	-1.35
pH 7	76.12	74.27	-1.85
pH 8	85.54	81.45	-4.09
pH 9	91.24	89.17	-2.07

*Due to the low solubility of the pH 1-5 solutions, no stability data could be determined.

[00180] Compound 2 has demonstrated solubility and stability in selected aqueous buffers and organic solvents. For the solvents screened, Compound 2 was most soluble in MeOH, >50 mg/mL, the lowest solubility was in *iso*-propyl alcohol, 0.7 mg/mL. The pH solubility profile displayed an increase in solubility with an increase in pH. Compound 1 has a pK_a of ~3.86 and this explains the pH solubility trend. The stability data obtained for the pH 1-5 samples gave inconclusive results due to the low solubility of Compound 2 in these buffers.

10

Example 15: Comparison of HPMC and Gelatin Capsules

[00181] Twenty capsules of both hydroxypropyl methylcellulose (HPMC, also known as Hypromellose) and gelatin were filled with 25 ± 1 mg of amorphous Compound 2 to determine if the lower water content found in HPMC capsules would retard the water uptake of the compound. Samples of Compound 2 in both capsule types were placed at 25°C/60%RH and 40°C/75%RH for 1 week. The samples were analyzed for water content, potency, and % purity (% area) at $t=0$ and $t=1$ week.

15

Preparation of Compound 2 HPMC and Gelatin Samples

20 [00182] 20 transparent size 00 HPMC capsules and 20 transparent size 00 gelatin capsules were hand filled with API.

[00183] Each capsules was filled with 25 ± 1 mg of API.

25 [00184] The two capsule types were both separated into two 30 cc HDPE bottles with caps and placed at both 25°C/60%RH and 40°C/75%RH for 1 week.

- 59 -

Sample Analysis at t=0

[00185] For the t=0 time point, Compound 2 was analyzed for water content, potency, and % purity (% area).

5 Water Content

[00186] Two samples of Compound 2 were taken at t=0 for water content. The first sample was taken after the HPMC capsules had been filled and the second sample was taken after the gelatin capsules had been filled. This sampling procedure was done to offset the water uptake that took place while the capsules were being filled.

10 [00187] 50.3 mg of Compound 2 was weighed into a crimp vial after the HPMC capsules had been filled.

[00188] The vial was immediately crimped for Karl Fischer analysis.

15 [00189] 50.4 mg of Compound 2 was weighed into a crimp vial after the gelatin capsules had been filled.

[00190] The vial was immediately crimped for Karl Fischer analysis.

20 Potency and % Purity (% Area)

[00191] 76.17 mg of Compound 2 was weighed directly into a 100-mL volumetric flask.

[00192] The flask was diluted to volume with ACN and inverted to mix.

25

[00193] A 1 mL aliquot was transferred directly into an HPLC vial for analysis.

[00194] The samples were stored at 40°C/75% RH and 20°C/60% RH for 1 week and then samples were analyzed by HPLC for % purity and % potency. The results are shown in Table 28.

30

- 60 -

Table 28. HPMC vs. Gelatin Potency and Purity Results for t=0 and t=1 week

Name	%Potency	% a/a Purity	Δ % a/a Purity
Sample t=0	86.3	98.95	N/A
HPMC Capsules, 25°C, t=1 week	90.2	98.95	0.00
HPMC Capsules, 40°C, t=1 week	89.8	98.74	-0.21
Gelatin Capsules, 25°C, t=1 week	90.1	98.95	0.00
Gelatin Capsules, 40°C, t=1 week	90.8	98.88	-0.07

[00195] The HPMC vs. gelatin capsule comparison was implemented to determine if the lower starting water content of HPMC capsules would hinder the absorption of water by Compound 2. This experiment was also performed to learn if an increase in water content lead to a decrease in potency and % purity (% area) of the compound. The results showed that HPMC capsules did in fact slow the uptake of water, relative to gelatin, by 3.74% when stored at 40°C/75%RH. The potency and % purity (% area) of Compound 2 was unchanged for all conditions tested after 1 week.

10

Example 16: Particle size distribution, powder flow, bulk density, tap density and milling feasibility of Compound 2

[00196] Compound 2 particle size distribution was determined by sieve screen analysis. A sample of Compound 2 was passed through a series of sieves, which included a 53, 106, 250, 500, 710, and 1000 μm mesh screen. Each screen was weighed before and after the sieving occurred to determine the amount of compound at each particle size.

15

[00197] The powder flow was determined on a FlowDex apparatus.

[00198] Bulk density was determined by filling a tared 100 mL graduated cylinder with Compound 2. The volume and weight of Compound 2 added was recorded and used to calculate its bulk density. Tap density was then determined by taking the same graduated cylinder filled with Compound 2 and placing it on an Autotap set for 100 cycles. The new powder volume was recorded and used to calculate the tap density.

20

25

- 61 -

[00199] 24.73 mg of Compound 2 was weighed directly into a tared 25 mL volumetric flask. The flask was diluted to volume with ACN and inverted to mix. A sample was taken to determine the % purity (% area) of the drug before milling took place. Milling was performed by taking 17.92 g of Compound 2 and passing this material
 5 it through a conical mill with an 1143 μm screen. 14.33 g of Compound 2 was recovered and re-analyzed for particle size distribution, bulk density, and tap density. 24.93 mg of milled Compound 2 was weighed directly into a tared 25 mL volumetric flask. The flask was diluted to volume with ACN and inverted to mix. This sample was taken to determine the % purity (% area) after Compound 2 had been milled. The results are
 10 shown in Tables 29, 30, 31 and 32.

Table 29. Bulk Compound 2 Particle Size Distribution

Sieve Size (μm)	Wt. Compound 2 (mg)	%Wt.	% Undersized
1000	1680.7	30.9	69.1
710	1355.2	24.9	44.2
500	1371.4	25.2	19.0
250	934.0	17.2	1.8
106	82.1	1.5	0.3
53	10.8	0.2	0.1
<53	3.0	0.1	0.0
Total Wt.	5437.2		

Table 30. Milled Compound 2 Particle Size Distribution (using 1143 μm screen)

Sieve Size (μm)	Wt. Compound 2 (mg)	%Wt.	% Undersized
1000	36.4	0.7	99.5
710	1258.8	23.5	76.0
500	1988.9	37.1	38.9
250	1691.5	31.6	7.3
106	335.8	6.3	1.0
53	40.9	0.8	0.2
<53	8.2	0.2	0.0
Total Wt.	5360.5		

Table 31. Bulk and Tap Density of Unmilled Compound 2

Wt. Compound 2	8.86 g
Bulk Volume	100 mL
Tapped Volume	78 mL
Bulk Density	0.089 g/mL
Tap Density	0.114 g/mL

Table 32. Bulk and Tap Density of Milled Compound 2

Wt. Compound 2	7.27 g
Bulk Volume	100 mL
Tapped Volume	74 mL
Bulk Density	0.073 g/mL
Tap Density	0.098 g/mL

5 % Purity of Compound 2 sample did not change with milling.

10 [00200] After Compound 2 had been milled it was blended with 2.5% w/w of colloidal silicon dioxide, Cab-O-Sil®, on a T2 Turbula blender for 2 minutes. The blended powder was collected and its flow properties were analyzed on a FlowDex apparatus.

15 [00201] The powder flow of Compound 2 was determined on a FlowDex. The first condition tested was bulk unmilled Compound 2. The powder was unable to pass through the largest available, 34 mm, orifice. The second condition tested was milled Compound 2 that had been blended with 2.5% w/w colloidal silicon dioxide. The flow of the milled and blended Compound 2 passed through a 34 mm orifice but failed to pass through a 32 mm orifice.

20 [00202] Due to the low density and large particle size distribution of the bulk Compound 2, a milling process was used. The milling process lowered the average particle size of Compound 2 from ~775 µm to ~560 µm without degrading the drug. Milling the compound did however aerate the compound causing a decrease in bulk and tap density.

Example 17: Dissolution Comparison

[00203] Dissolution of three forms of solid sodium salt were analyzed, a monosodium trihydrate (Compound 6), a monosodium salt dihydrate (Compound 7) and
5 amorphous Compound 2.

Preparation of Crystalline Trihydrate (Compound 6) Capsules

[00204] The crystalline material was made by exposing amorphous Compound 2 to ambient temperature/75% RH for 24 hrs. These conditions were created using a saturated
10 sodium chloride solution sealed in a desiccant chamber. Once the crystalline material had been created it was collected and stored at 2-8°C until dissolution testing took place. Two samples for dissolution were prepared by weighing 25 mg $\pm$ 1 mg into size 00 white opaque gelatin capsules.

15 Preparation of Crystalline Dihydrate (Compound 7) Capsules

[00205] Crystalline Compound 7 dihydrate was made by placing a sample of the *iso*-propanol solvate of Compound 2 at ambient temperature and humidity conditions for 2 weeks. The *iso*-propanol solvate of Compound 2 readily converts to the dihydrate. Once Compound 7 had been prepared, it was collected and stored at 2-8°C until
20 dissolution testing was conducted. Two samples for dissolution were prepared by weighing 25 mg $\pm$ 1 mg into size 00 white opaque gelatin capsules.

Preparation of Compound 2 Capsules

[00206] Two samples for dissolution were prepared by weighing 25 mg $\pm$ 1 mg of
25 amorphous Compound 2 into size 00 white opaque gelatin capsules.

[00207] The dissolution materials and parameters are set out in Table 33. At each pull time ~6 mL of media was removed from each vessel and filtered through a 0.45 μ m nylon filter. The first 5 mL of solution was discarded and the final 1 mL was collected in
30 a UPLC vial for analysis.

- 64 -

Table 33. Dissolution Parameters and Materials.

Dissolution Media	pH 6.8 Phosphate Buffer
Dissolution Media Volume per Vessel	900 mL
Bath Temperature	37.0 ± 0.5°C
Paddle Speed	50 RPM for 1st hour, 150 RPM for 2 nd hour
Pull Times	15, 30, 45, 60, and 120 minutes

[00208] The mean dissolution values at each time point for each sample were evaluated are provided in Table 34.

5

Table 34. Dissolution Results for Different Crystalline Forms of Compound 2

Time (mins)	% Dissolution of Compound 7	%Dissolution of Compound 6	% Dissolution of Compound 2
15	72.8	39.4	77.8
30	74.7	56.5	83.6
45	77.4	64.4	86.3
60	78.2	69.6	88.8
120	80.9	88.9	92.9

[00209] As expected the crystalline forms of Compound 2 had the slowest dissolution rate, while amorphous Compound 2 dissolved considerably faster.

10

Example 18: Formulation

[00210] The components set out in Table 35 were mixed to provide a homogenous mixture and the mixture was placed in gelatin or HPMC capsules.

5 Table 35. Prototype formulations of amorphous Compound 2

Component	Grade	25 mg Formulation	10 mg Formulation	25 mg Formulation	25 mg Formulation
Compound 2	N/A	6.49%	6.49%	6.49%	5.06%
Colloidal Silicon Dioxide	Aerosil 200 Pharma (USP/NF, EP, JP)	0.5%	0.5%	0.5%	0.5%
Microcrystalline Cellulose (MCC)	Avicel PH102 (USP/NF, EP, JP)	92.01%	92.01%	92.01%	-
Mannitol	Fast-Flo (USP/NF, EP, JP)	-	-	-	93.44%
Magnesium Stearate	Vegetable Grade (USP/NF, EP, JP)	1.0%	1.0%	1.0%	-
Stearic Acid	Hystyrene (USP/NF, EP, JP)	-	-	-	1.0%
	Total	100%	100%	100%	100%
Capsule Shell Type		HPMC (VCaps Plus)	HPMC (VCaps Plus)	Gelatin (Coni-Snap)	HPMC (VCaps Plus)
Capsule Fill Weight		440 mg	176 mg	440 mg	565 mg
Capsule Size		00	2	00	00

[00211] Stability of selected 25 mg formulations is shown at one month at 40°C / 75°C RH in Table 36.

Table 36. Stability.

	HMPC / Mannitol		HPMC / MCC		Gelatin / MCC	
	initial	one month	initial	one month	initial	one month
Appearance	white opaque 00 capsule white / off white powder	No change	white opaque 00 capsule white / off white powder	No change	white opaque 00 capsule white / off white powder	No change
Assay	100.1%	95.4%	98.0%	95.4%	97.4%	96.8%
Related substances	0.20%	1.26%	0.27%	0.7%	0.24%	0.57%
Water content	1.13%	1.56%	5.52%	5.92%	6.53%	7.13%

Example 19: Preparation of Compound 2 from free Acid Compound 1

5 **[00212]** Compound 1 (31.35g, 61.8 mmol, 95.82% purity) was dissolved in
 dichloromethane (DCM) (150 mL) and treated with sodium ethoxide solution (20.05 mL,
 21% w/w). The mixture was evaporated to dryness and then dissolved in ethyl acetate
 (110 mL). To this solution was added *iso*-propanol (315 mL) dropwise with stirring
 causing rapid crystallization. Twenty minutes after complete addition of *iso*-propanol,
 the crystals were filtered, washed with *iso*-propanol (80 mL) and dried on the sinter for
 10 approximately 3h. this gave 28.71 g cream powder. This material was dissolved in 290
 mL of distilled water with warming (40°C) and stirred at ambient temperature for 1h with
 resulting crystallization. The mixture was filtered and the residue dried under vacuum
 giving 21.35 g (65%) white solid. HPLC analysis revealed the material was >98% e.e.
 and in 99.3% purity.

15


20 **[00213]** m/z (ES⁻) 506.2 [MH⁺, 100%], 507.2 [13C₁-MH⁺, 40%]; HRMS C₃₂H₂₈NO₅
 requires 506.1969, found 506.1967; ¹H NMR (CDCl₃, 300 MHz) δ 2.08 (1H*, dd, *J* 16.6,
 6.4), 2.83 (1H, dd, *J* 15.9, 6.4), 3.03 (1H, dd, *J* 15.9, 6.4), 3.36 (1H*, m), 3.55 (3H*, s),
 3.66 (3H, s), 4.29-4.47 (3H, 2H*, m), 4.68 (1H*, d, *J* 11.0, 4.83 (2H, m), 4.83 (1H*, m),
 4.91 (1H*, d, *J* 17.0, 5.28 (1H*, s), 5.31 (1H, s), 6.21 (1H, d, *J* 8.3), 6.46 (1H, d, *J* 8.3),
 6.48 (1H*, d, *J* 8.3), 6.94-7.32 (15H, m); ¹³C NMR (CDCl₃, 500 MHz) δ 25.5 (CH₂),
 26.0 (*CH₂), 42.8 (*CH₂), 45.8 (CH₂), 55.0, 55.8, 56.1, 56.7, 74.2 (*CH₂), 74.9 (CH₂),

- 67 -

110.2 (CH), 110.7 (*CH), 121.1 (CH), 122.0 (*CH), 126.4, 126.7, 126.8, 127.0, 127.8, 127.9, 128.3, 128.5, 128.6, 128.7, 128.8, 129.0, 129.5, 129.5, 129.8, 137.5 (q), 127.7 (*q), 139.3 (q), 139.3 (*q), 139.9 (q), 140.7 (*q), 144.4 (q), 144.7 (*q) 150.7 (*q), 151.6 (q), 172.2 (q), 172.7 (*q), 177.7 (q); $[\alpha]_D^{25} = -39.1$ (CH₂Cl₂, c0.68); IR (cm⁻¹, KBr disc)
 5 3425 (O-H), 1626 (C=O), 1601 (C=O). * denotes the minor rotomer.

Example 20: Acylation of isoquinoline and crystallization

Acylation Step



[00214] A suspension of dichloromethane (DCM), isoquinoline (1.0eq) and pyridine (6.0eq) was cooled to $-12 \pm 2^\circ\text{C}$ under an inert nitrogen atmosphere. Chlorotrimethylsilane (4.0eq) was added gradually to the suspension while maintaining an internal temperature of -10°C or less. After complete addition an approximately homogeneous solution will result. The reaction mixture was agitated for a minimum of 20 minutes and the internal temperature adjusted to $-12 \pm 2^\circ\text{C}$. A DCM solution of diphenylacetyl chloride (0.9eq) was then added gradually to the reaction mixture while maintaining an internal temperature of less than -10°C . The reaction mixture was stirred for a minimum of 15mins following complete addition while maintaining an internal temperature of less than -10°C .


15

20


[00215] The reaction was quenched with 2M hydrochloric acid and the mixture warmed to $+20 \pm 5^\circ\text{C}$. Agitation was stopped and the biphasic mixture was left to settle for a minimum of 15 minutes. The lower (organic) phase was separated. Sodium ethoxide solution (21% in ethanol, 1.0eq) was added to the organic phase and the resulting solution was evaporated to give the sodium salt ethanol solvate Compound 4.

25

- 68 -

Crystallization Step

- 5 **[00216]** The crude sodium salt ethanol solvate Compound 4 was dissolved in ethyl acetate (EA) and then concentrated. The residue was dissolved in ethyl acetate and then stirred at $+20 \pm 5^\circ\text{C}$. Isopropanol was added gradually in a controlled addition to the stirred ethyl acetate solution. This causes crystallization of the *iso*-propanol solvate, Compound 5. Following complete addition the mixture was stirred for one hour. The
- 10 crystals were filtered and washed with *iso*-propanol. The crystals were dried under vacuum until *iso*-propanol levels are less than 10%. The crystals were added to a stirred volume of RO water causing rapid dissolution to occur. The resulting solution was stirred for two hours allowing a thick precipitate to form. The resulting slurry was then freeze-
- 15 dried giving Compound 2 as an off-white powder.

Example 21:Pyrazole Active Ester Formation

20


- [00217]** A glass or stainless steel jacketed vessel was placed under an inert atmosphere. To the vessel were charged pyrazole (1.1eq), *N*-methylmorpholine (NMM) (1.3eq) and ethyl acetate. An ethyl acetate solution of diphenylacetyl chloride (1.0eq) was added gradually. Cooling of the reaction vessel was applied so as to maintain an
- 25 internal temperature below $+30^\circ\text{C}$. Following complete addition the contents were stirred for a minimum of 20 minutes. The reaction mixture was washed with water, 1M

- 69 -

sulphuric acid (2x), saturated aqueous sodium bicarbonate (2x), water and brine. The ethyl acetate phase was concentrated and the residue was stripped with heptane.

[00218] The residue was heated to 70°C in heptane so as to dissolve all solids. The resulting solution was cooled and held at 15±5°C for 1h with concomitant crystallization. The crystals were filtered and dried for a minimum of 16h. Yield: 80-90% from diphenylacetyl chloride.

Isoquinoline Acylation



[00219] A glass lined or stainless steel vessel was placed under an inert atmosphere. To the vessel was charged DMF, tetramethylguanidine (1.03eq) and isoquinoline (1.0eq). The mixture was stirred for approximately 1h to allow dissolution to occur (only partial dissolution was expected at this stage). To the reaction mixture was charged pyrazole active ester (1.2eq). The reaction mixture was stirred for a minimum of 16h. An IPC (HPLC) was performed to verify the extent of reaction (pass condition: < 5.00% isoquinoline remaining). Dimethylethylenediamine (0.3eq) was charged to the reaction mixture and stirring continued for a further 2h. An IPC (HPLC) was performed for pyrazole active ester (pass condition: < 0.10% pyrazole active ester).

[00220] The reaction mixture was diluted with toluene and washed with 1M sulfuric acid (2x) and water (2x). The organic phase was reduced in volume through evaporation of solvent. Sodium ethoxide (1.0eq) was charged to the reaction mixture. The remaining solvent was evaporated from the reaction mixture. The residue was evaporated from ethyl acetate.

- 70 -

[00221] The crude product was agitated in ethyl acetate and the mixture transferred to a stirred vessel. *Iso*-propanol was charged to the ethyl acetate solution in a controlled addition causing crystallization to occur. The mixture was stirred for a minimum of 1h. The crystals were filtered and washed with a small volume of *iso*-propanol. The crystals were dried under vacuum for a minimum of 16h giving Compound 5.

[00222] Water was charged to a glass lined or stainless steel vessel. The internal temperature was adjusted to $40\pm 2^{\circ}\text{C}$. The crystals of Compound 5 were slowly charged to the water, allowing dissolution to occur. The warm solution was dispensed in to lyoguard trays and loaded in to the freeze-dryer. Primary drying was conducted with a shelf temperature of -5°C over at least 3 days. The secondary drying phase is conducted with a shelf temperature of $+25^{\circ}\text{C}$ over at least 24h. An IPC (KF) was performed to verify acceptable water content (pass condition: $<15.0\%$ water). Compound 2 was removed from the lyoguard trays and placed in appropriate containment. Yield: 80-90% from isoquinoline.

Example 22:

Bioavailability of Compound 2

[00223] Compound 2 in HPMC capsules was orally administered in varying amounts, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg, once a day for seven days to healthy male subjects (18-55 years of age).

[00224] Blood samples were taken at regular intervals following each dose and the plasma derived from the blood samples analyzed for levels of Compound 1. The data obtained was used to calculate pharmacological parameters as shown in Table 37.

Table 37: Pharmacological parameters for Compound 2

Dose (mg)	Mean (SD) by Cohort					
	$T_{\max}$ (hr)	$C_{\max}$ (ng/mL)	AUC_{0-24} (hr*ng/mL)	K_{el} (1/hr)	$T_{1/2}$ (hr)	$AUC_{0-\infty}$ (hr*ng/mL)
10	1.10 (0.74) n = 15	34.5 (18.3) n = 15	66.4 (22.2) n = 15	0.123 (0.071) n = 15	8.05 (5.31) n = 15	69.9 (24.4) n = 15

- 71 -

Dose (mg)	Mean (SD) by Cohort					
	T _{max} (hr)	C _{max} (ng/mL)	AUC ₀₋₂₄ (hr*ng/mL)	K _{el} (1/hr)	T _{1/2} (hr)	AUC _{0-∞} (hr*ng/mL)
25	1.50 (0.89) n = 8	112.6 (78.2) n = 8	194.6 (72.5) n = 8	0.079 (0.029) n = 7	10.68 (6.56) n = 7	223.8 (60.0) n = 7
50	1.0 (0.84) n = 6	207.6 (101.8) n = 6	334.5 (83.6) n = 6	0.075 (0.044) n = 6	13.44 (9.40) n = 6	353.5 (78.4) n = 6
100	1.29 (0.95) n = 7	451.3 (310.2) n = 7	720.9 (181.1) n = 7	0.066 (0.017) n = 7	11.20 (3.21) n = 7	758.7 (171.0) n = 7
200	1.14 (0.63) n = 7	589.0 (367.0) n = 7	1307.5 (572.3) n = 7	0.073 (0.038) n = 7	13.15 (9.43) n = 7	1369.1 (583.7) n = 7

n=number of subjects at each dose level.

Example 23:Pharmacokinetic Analysis of Compounds 2 (Amorphous), 6, 7 and 1 in Male Beagle Dogs5 Following a Single Oral Dose

[00225] The study was designed to compare the PK profiles of the following four forms of Compound 1 administered as single oral capsules in fasted state. The randomization schedule for the animals is summarized in the table below. Briefly, the study consisted of 4 male dogs; each received single 10 mg/kg doses of each of the four compounds: Compound 2 sodium salt amorphous, Compound 6, Compound 7 and Compound 1 free carboxylic acid. There was a washout period of 4 days between dosing. The blood samples were collected from each animal at predetermined times on the study Days 1, 4, 8 and 11. The plasma was analyzed for Compound 1 by a validated HPLC-MS/MS assay.

15

Animal	Day 1	Day 4	Day 8	Day 11
1	A	D	C	B
2	B	A	D	C
3	C	B	A	D
4	D	C	B	A

A – Compound 2 (Amorphous)

B – Compound 6

- 72 -

C – Compound 7

D – Compound 1

[00226] Descriptive PK parameters were determined by standard model independent methods (Gibaldi and Perrier, 1982) based on the individual plasma concentration-time data. Plasma concentrations were rounded to 3 significant figures. Plasma samples with concentrations below the quantifiable assay limit ($BQL < 2.00 \text{ ng/mL}$) were assigned values of zero for mean calculations. For PK calculations, BQL was set to zero from the pre-dose time up to the time of the first quantifiable concentration and thereafter was set as missing. Nominal time points were used for all calculations.

- C_{max} is the observed maximum plasma concentration after dosing.
- T_{max} is the time to reach C_{max} .
- $T_{1/2}$ is apparent half-life calculated by $\ln(2)/\lambda$ where λ is the rate constant for the log-linear portion of the terminal phase. A minimum of three values in the post-distribution phase of the plasma concentration-time curve is required for calculation of λ .
- $AUC(0-T)$ is the area under the plasma concentration-time curve from time zero to the time of the last measurable plasma concentration determined using the linear trapezoidal rule.
- $AUC(0-\infty)$ is the area under the plasma concentration-time curve from time zero to infinity. It is calculated by summing $AUC(0-T)$ and the extrapolated area from the T to infinity.

[00227] PK analyses were performed by noncompartmental analysis using model 200 in WinNonlin Professional 6.1 (Pharsight Corp., Mountain View, CA).

[00228] Individual, mean and SD values for Compound 1 plasma concentrations and PK parameters following Compound 2 (amorphous), Compound 6, Compound 7 and Compound 1 free carboxylic acid are presented in Tables 38, 39, 40 and 41, respectively. Compound 1 mean PK parameters are summarized in Table 42. Compound 1 Mean

- 73 -

plasma concentration-time profiles following different forms are shown in Figure 11 and the mean C_{max} and AUC(0-inf) are presented in Figure 12.

[00229] Following a single oral dose of Compound 1 at 10 mg/kg, the median T_{max} values were 0.750, 1.00, 1.00 and 2.00 hours for Compound 2 sodium salt amorphous, Compound 6, Compound 7 and Compound 1 free carboxylic acid, respectively (Table 42). The corresponding mean C_{max} values were 1590 ± 534, 1320 ± 1050, 1260 ± 428 and 294 ± 238 ng/mL, respectively (Table 42). Mean AUC(0-inf) values were 1840 ± 516, 1930 ± 1240, 2440 ± 542 and 680 ± 412 ng·h/mL, respectively. The AUC following Compound 6 and free carboxylic acid had higher inter-subject variability than the Compound 2 amorphous and Compound 7 hydrate (%CV values ranging from 60.6% to 81.1%; see Table 42). The Compound 7 hydrate resulted in the highest mean AUC while the free carboxylic acid Compound 1 resulted in the lowest AUC. Mean harmonic T_{1/2} values were 2.49 ± 0.391, 2.82 ± 1.18, 4.36 ± 3.16 and 2.11 ± 0.115 hours for Compound 2 sodium salt amorphous, Compound 6, Compound 6 and free carboxylic acid Compound 1, respectively (Figure 11 and Table 42).

[00230] The longest T_{max} was observed following the free carboxylic acid Compound 1 at a median value of 2 hours compared with 0.75 to 1 hour for Compound 2 (amorphous), Compound 6, and Compound 7. The highest mean C_{max} value was observed following Compound 2 (amorphous) (1590 ± 534 ng/mL) and the highest mean AUC value was observed following Compound 6 (2440 ± 542 ng·h/mL).

Table 38: Plasma Concentrations (ng/mL) and PK Parameters of Compound 1 in Dogs Following a Single Oral 10 mg/kg Dose of Compound 2 Amorphous Form

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
	Predose	BQL	BQL	BQL	BQL	4	0.00	0.00	NA
	0.25	BQL	BQL	BQL	26.5	4	6.63	13.3	200
	0.5	597	14.1	BQL	2,270	4	720	1,070	149
	0.75	1,110	146	1,750	1,090	4	1,020	661	64.5
	1	830	1,220	835	880	4	941	187	19.9
	2	148	763	195	345	4	363	280	77.1

- 74 -

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
	4	25.5	48.6	44.4	54.1	4	43.2	12.4	28.8
	8	9.07	19.4	16.4	23.1	4	17.0	5.95	35.0
	12	2.81	6.39	2.95	7.53	4	4.92	2.40	48.8
	24	BQL	20.7	6.83	BQL	4	6.88	9.76	142
Tmax ^a , h		0.750	1.00	0.750	0.500	4	0.750	0.5-1	27.2
Cmax, ng/mL		1,110	1,220	1,750	2,270	4	1,590	534	33.6
AUC(0-T), ng·h/mL		1,290	2,350	1,520	2,180	4	1,830	512	27.9
AUC(0-inf), ng·h/mL		1,300	2,350	1,520	2,220	4	1,840	516	28.0
T _{1/2} ^b , h		2.51	2.73	2.05	2.81	4	2.49	0.391	15.7

^a Expressed as median and range^b Expressed as harmonic mean and pseudo SD

BQL - Below the Quantifiable Limit < 2.00 ng/mL

NA - Not Applicable

Table 39: Plasma Concentrations (ng/mL) and PK Parameters of Compound 1 in Dogs Following a Single Oral 10 mg/kg Dose of Compound 6

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
	Predose	BQL	BQL	BQL	BQL	4	0.00	0.00	NA
	0.25	BQL	313	BQL	1,180	4	373	558	149
	0.5	BQL	255	8.80	2,560	4	706	1,240	176
	0.75	5.31	588	180	1,520	4	573	677	118
	1	27.7	1,790	252	857	4	732	788	108
	2	658	1,170	160	161	4	537	483	89.8
	4	55.2	52.0	24.0	70.9	4	50.5	19.5	38.6
	8	9.17	12.0	12.1	12.8	4	11.5	1.60	13.9
	12	4.50	5.90	4.11	5.68	4	5.05	0.877	17.4
	24	BQL	2.00	10.3	BQL	4	3.08	4.91	159
Tmax ^a , h		2.00	1.00	1.00	0.500	4	1.00	0.5-2	55.9
Cmax, ng/mL		658	1,790	252	2,560	4	1,320	1,050	80.2
AUC(0-T), ng·h/mL		1,220	3,430	660	2,370	4	1,920	1,230	64.2
AUC(0-inf), ng·h/mL		1,230	3,440	661	2,380	4	1,930	1,240	64.2
T _{1/2} ^b , h		2.21	6.48	3.14	2.03	4	2.82	1.18	41.8

^a Expressed as median and range^b Expressed as harmonic mean and pseudo SD

BQL - Below the Quantifiable Limit < 2.00 ng/mL

- 75 -

NA - Not Applicable

Table 40: Plasma Concentrations (ng/mL) and PK Parameters of Compound 1 in Dogs Following a Single Oral 10 mg/kg Dose of Compound 6

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
	Predose	BQL	BQL	BQL	BQL	4	0.00	0.00	NA
	0.25	2.72	BQL	10.0	BQL	4	3.18	4.72	149
	0.5	16.1	199	813	83.2	4	278	365	131
	0.75	512	372	415	672	4	493	133	27.0
	1	1,060	269	857	1,850	4	1,010	653	64.8
	2	792	1,270	428	932	4	856	349	40.7
	4	67.9	60.1	49.0	83.5	4	65.1	14.5	22.3
	8	16.9	15.2	10.2	18.1	4	15.1	3.48	23.0
	12	5.79	4.22	6.63	8.07	4	6.18	1.61	26.0
	24	3.56	2.75	3.21	BQL	4	2.38	1.62	68.1
	T _{max} ^a , h	1.00	2.00	1.00	1.00	4	1.00	1-2	40.0
	C _{max} , ng/mL	1,060	1,270	857	1,850	4	1,260	428	34.0
	AUC(0-T), ng·h/mL	2,320	2,510	1,750	3,080	4	2,410	550	22.8
	AUC(0-inf), ng·h/mL	2,340	2,520	1,790	3,110	4	2,440	542	22.2
	T _{1/2} ^b , h	5.21	4.93	9.97	2.37	4	4.36	3.16	72.5

^a Expressed as median and range^b Expressed as harmonic mean and pseudo SD

BQL - Below the Quantifiable Limit < 2.00 ng/mL

NA - Not Applicable

5 Table 41: Plasma Concentrations (ng/mL) and PK Parameters of Compound 1 in Dogs Following a Single Oral 10 mg/kg Dose of Compound 1 in Free Carboxylic Acid Form

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
	Predose	BQL	BQL	BQL	BQL	4	0.00	0.00	NA
	0.25	BQL	3.55	BQL	BQL	4	0.888	1.78	200
	0.5	15.9	5.52	BQL	BQL	4	5.36	7.50	140
	0.75	40.2	5.18	BQL	BQL	4	11.3	19.4	171
	1	139	8.08	2.32	81.4	4	57.7	65.1	113
	2	38.3	392	62.1	582	4	269	264	98.3
	4	16.1	35.0	29.7	29.6	4	27.6	8.07	29.2
	8	5.44	11.3	5.88	5.83	4	7.11	2.80	39.3
	12	BQL	2.15	BQL	2.31	4	1.12	1.29	115
	24	BQL	BQL	BQL	BQL	4	0.00	0.00	NA

- 76 -

Parameter	Time (h)	Dog I.D.				N	Mean	SD	%CV
		301	302	303	304				
Tmax ^a , h		1.00	2.00	2.00	2.00	4	2.00	1-2	28.6
Cmax, ng/mL		139	392	62.1	582	4	294	238	81.1
AUC(0-T), ng·h/mL		218	751	195	1,040	4	551	415	75.3
AUC(0-inf), ng·h/mL		234	758	ND	1,050	3	680	412	60.7
T _{1/2} ^b , h		2.18	1.99	ND	2.17	3	2.11	0.115	5.45

^a Expressed as median and range^b Expressed as harmonic mean and pseudo SD

BQL - Below the Quantifiable Limit < 2.00 ng/mL

NA - Not Applicable

ND - Not Determined

Table 42: Summary of Mean PK Parameters of Compound 1 in Dogs Following Compound 1, Compound 2 (Amorphous), Compound 6, and Compound 7

Compound Administered	Statistic	Tmax ^a (h)	Cmax (ng/mL)	AUC(0-T) (ng·h/mL)	AUC(0-inf) (ng·h/mL)	T _{1/2} ^b (h)
Compound 2 Sodium Salt Amorphous	N	4	4	4	4	4
	Mean	0.750	159	1,840	1,840	2.49
	SD	0.5-1	53.4	515	516	0.391
	CV%	27.2	33.6	28.0	28.0	15.7
Compound 6	N	4	4	4	4	4
	Mean	1.00	132	1,920	1,930	2.82
	SD	0.5-2	105	1,230	1,240	1.18
	CV%	55.9	80.2	64.0	64.2	41.8
Compound 7	N	4	4	4	4	4
	Mean	1.00	126	2,420	2,440	4.36
	SD	1-2	42.8	561	542	3.16
	CV%	40.0	34.0	23.2	22.2	72.5
Compound 1	N	4	4	3	3	3
	Mean	2.00	29.4	680	680	2.11
	SD	1-2	23.8	412	412	0.115
	CV%	28.6	81.1	60.6	60.7	5.45

- 77 -

Compound Administered	Statistic	Tmax ^a (h)	Cmax (ng/mL)	AUC(0-T) (ng·h/mL)	AUC(0-inf) (ng·h/mL)	T _{1/2} ^b (h)
^a Expressed as median and range						
^b Expressed as harmonic mean and pseudo SD						

[00231] The above is a detailed description of particular embodiments of the invention. It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

- 78 -

WHAT IS CLAIMED:

1. The sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and solvates thereof.
5
2. The sodium salt according to claim 1 in amorphous form.
3. The sodium salt according to claim 1 in the form of a crystalline solvate.
- 10 4. The sodium salt according to claim 3 wherein the solvate is an ethanol solvate, *iso*-propanol solvate, or a hydrate having about 2 to about 5 molecules of water.
5. The sodium salt according to claim 4 wherein the solvate is an ethanol or *iso*-propanol solvate.
15
6. The sodium salt according to claim 4 wherein the solvate is a hydrate having about 2 molecules of water.
7. The sodium salt according to claim 4 wherein the solvate is a hydrate having about
20 3 to about 5 molecules of water.
8. The sodium salt hydrate according to claim 6, wherein said crystalline solvate exhibits an x-ray powder diffraction pattern comprising a peak at about 19.3 degrees 2 θ .
- 25 9. The sodium salt hydrate according to claim 8, wherein said x-ray powder diffraction pattern further exhibits a peak at about 18.2 degrees 2 θ .
10. The sodium salt hydrate according to claim 9, wherein said crystalline solvate exhibits a solid state ¹³C NMR spectrum comprising peaks at about 55.7, about 128.2, and
30 about 151.3 ppm.

- 79 -

11. The sodium salt hydrate according to claim 7, wherein said crystalline solvate exhibits an x-ray powder diffraction pattern comprising a peak at about 15.2 degrees 2θ .
12. The sodium salt hydrate according to claim 11, wherein said X-ray powder
5 diffraction pattern further comprises at least two peaks selected from the group consisting of about 4.8, about 7.3, about 12.0, about 12.6, about 23.5, and about 24.5 degrees 2θ .
13. The sodium salt hydrate according to claim 12, wherein said crystalline solvate exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 53.7, about 122.9, and
10 about 128.1 ppm.
14. The ethanol solvate according to claim 5 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising a peak at about 14.3 degrees 2θ .
15. 15. The ethanol solvate according to claim 5 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising a peak at about 14.7 degrees 2θ .
16. The ethanol solvate according to claim 5 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising at least two peaks selected from a group
20 comprising about 14.3, about 14.7, about 26.9, and about 29.7 degrees 2θ .
17. The ethanol solvate according to claim 16 wherein said crystalline solvate exhibits a solid state ^{13}C NMR spectrum comprising peaks at about 18.4, about 139.7, and about 141.4 ppm.
25
18. The *iso*-propanol solvate according to claim 5 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising at least one peak selected from the group consisting of about 20.6, about 26.6, about 27.2, about 28.3, and about 29.3 degrees 2θ .

30

- 80 -

19. The *iso*-propanol solvate according to claim 18 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern comprising at least two peaks selected from the group consisting of about 25.0, about 26.0, about 26.6, about 27.2, about 28.3, and about 29.3 degrees 2 θ .

5

20. The *iso*-propanol solvate according to claim 18 wherein said crystalline solvate exhibits an X-ray powder diffraction pattern further comprising at least one peak selected from the group consisting of about 10.8, about 14.0, about 21.1, about 21.9, and about 22.5 degrees 2 θ .

10

21. The *iso*-propanol solvate according to claim 20 wherein said crystalline solvate exhibits a solid state ¹³C NMR spectrum comprising peaks at about 63.1 and about 140.7 ppm.

15

22. (*S*)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.

20

23. A pharmaceutical composition comprising (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid, its sodium salt or a solvate of the sodium salt together with a pharmaceutically acceptable carrier, diluent or excipient.

25

24. A pharmaceutical composition according to claim 23 comprising the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid.

25. A pharmaceutical composition according to claim 24 wherein the sodium salt is in amorphous form.

30

26. A pharmaceutical composition according to any one of claims 23-25 formulated for oral delivery.

- 81 -

27. A method of preparing the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid or a solvate thereof comprising:

- 5 (i) Treating (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid with sodium alkoxide;
- (ii) forming a crystalline alcohol solvate of the resulting sodium salt formed in (i); and
- (iii) recrystallizing the solvate.

10

28. A method according to claim 27 wherein the crystalline alcohol solvate is an ethanol solvate, an *iso*-propanol solvate, or a hydrate having about 2 to about 5 molecules of water.

15 29. A method according to claim 27 wherein the alcohol molecule of the crystalline alcohol solvate formed in step (ii) is exchanged for another solvate molecule before, during, or after step (iii).

20 30. A method according to any one of claims 27 or claim 29 wherein the solvate recrystallized in step (iii) is an *iso*-propanol solvate.

31. A method according to claim 29 wherein the solvate formed is a hydrate.


25 32. A method according to any one of claims 27 to 31, comprising the further step of drying the solvate.

30 33. A method according to any one of claims 27 to 31 further comprising acidification of the sodium salt to form (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.

- 82 -

34. A method of preparing an alcohol solvate of the sodium salt of (*S*)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid comprising the steps of:

- 5 (i) acylating the isoquinoline nitrogen atom of (*S*)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid with an activated cyclic amide of the formula:



wherein ring A is a 5 membered nitrogen-containing heterocycle; and

- (ii) treating the product of step (i) with an alkoxide salt in an alcohol solvent.

1/14




Figure 1

2/14




Figure 2

3/14




Figure 3

4/14




Figure 4

5/14




Figure 5

6/14




Figure 6

7/14




Figure 7

8/14




Figure 8

9/14




Figure 9

10/14







Figure 10


11/14

Linear Scale**Figure 11A**

12/14

Log Scale**Figure 11B**

13/14



14/14

AUC




FIGURE: 12B

- (A) Compound 2 Sodium Salt Amorphous
- (B) Compound 6
- (C) Compound 7
- (D) Compound 1 Free Carboxylic Acid

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2011/001096

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D217/26
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 246 943 A (BLANKLEY CLIFTON J [US] ET AL) 21 September 1993 (1993-09-21) cited in the application column 35; example 47	22,23,26
X	S KLUTCHKO: "Tetrahydroisoquinoline derivatives with AT2-specific angiotensin II reception binding inhibitory activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 1, 6 January 1994 (1994-01-06), pages 57-62, XP55005280, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(01)81122-7 cited in the application page 57; table 1; compound PD 126055 ----- -/-	22,23,26



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 August 2011

Date of mailing of the international search report

29/08/2011

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Duval, Eric

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2011/001096

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 2011/088504 A1 (SPINIFEX PHARM PTY LTD [AU]; MCCARTHY THOMAS DAVID [AU]; BAKER ANDREW) 28 July 2011 (2011-07-28) page 34, line 2 page 16; compound 1 -----	1,22-24, 26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2011/001096

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5246943	A	21-09-1993	
		AU 671283 B2	22-08-1996
		AU 4290693 A	13-12-1993
		AU 682136 B2	18-09-1997
		AU 6562396 A	07-11-1996
		CA 2134765 A1	25-11-1993
		CZ 9402828 A3	13-09-1995
		EP 0641326 A1	08-03-1995
		HU 217069 B	29-11-1999
		JP 7508266 T	14-09-1995
		NO 944421 A	18-11-1994
		NZ 252856 A	22-08-1997
		RU 2135473 C1	27-08-1999
		SK 138594 A3	11-07-1995
		US 5350757 A	27-09-1994
		WO 9323378 A1	25-11-1993

WO 2011088504	A1	28-07-2011	NONE
